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ABSTRACT
CXCR4 is a chemokine receptor that is overexpressed in multiple disease states,
including cancer. Understanding the mechanisms by which cells regulate CXCR4
expression is of high importance, as they can reveal downstream effectors that can
potentially be targeted pharmacologically to more effectively treat diseases with fewer
side effects.
CXCR4 is internalized in response to stimulation by its ligand CXCL12, and
localizes to early endosomes as part of a homologous desensitization mechanism. From
the endosome, CXCR4 can enter one of two pathways whereby it is either recycled back
to the plasma membrane, where it can undergo another signaling event, or it is targeted
for lysosomal degradation via the ESCRT pathway in a ubiquitin-dependent fashion. It is
known that an interaction between the proteins β-arrestin-1 and STAM-1 (a subunit of
ESCRT-0) on endosomal membranes plays a key role in sorting CXCR4 to the
degradative pathway, and that disrupting this interaction can accelerate CXCR4
degradation. Therefore, the β-arrestin-1/STAM-1 complex represents a potential target by
which to modulate cellular CXCR4 levels.
The goal of this project was to develop an assay that can monitor the interaction
between β-arrestin-1 and STAM-1 in live cells, which can be used to study their binding
under various conditions. An important use of the assay could be to assess the ability of
various small molecules to interrupt this interaction, which could potentially be
xv

developed as novel therapeutics for the treatment of diseases that overexpress CXCR4. In
addition, the assay could be applied to a variety of experiments in order to further
elucidate the mechanisms by which the β-arrestin-1/STAM-1 complex interacts with of
other proteins to modulate the sorting of CXCR4 on endosomes.
The assay designed in this project utilizes bioluminescence resonance energy
transfer (BRET) as a measurement of the interaction status by the co-expression of
STAM1-Rluc (Renilla luciferase) with β-arrestin1-YFP. The addition of a
coelenterazine(h) substrate induces the emission of light from Rluc, which is absorbed by
the yellow fluorescent protein (YFP) and emitted at a different wavelength, if the proteins
are interacting. It was expected that expression of the two fusion proteins would yield a
relatively low BRET signal in cells that had not been stimulated with CXCL12. However,
following CXCL12 stimulation, a significantly higher BRET signal was expected, since
CXCR4 is rapidly internalized to endosomes upon ligand binding.
After attempting to use BRET to detect an interaction between two proteins
whose interaction has already been shown by BRET, and using BRET to examine the
interaction between two proteins that are not expected to interact, it was determined that
BRET measurements between STAM1-Rluc and β-arrestin1-YFP were likely showing a
slight interaction between the two proteins. No differences were seen in BRET between
cells stimulated with CXCL12 or vehicle. It is concluded from the obtained results that
further optimization steps are required for the assay described here to be amenable to any
future studies of the interaction between STAM-1 and β-arrestin-1.

xvi

CHAPTER 1
INTRODUCTION
Overview of G Protein-Coupled Receptors
G protein-coupled receptors (GPCRs) are a superfamily of proteins that are
mainly characterized by the possession of seven membrane-spanning domains,
functioning as cellular surface receptors that propagate signals from the outside to the
inside of the cell. 1 GPCR signaling is highly conserved across many different organisms,
and plays a role in a multitude of signaling pathways in humans. 1 As such, the
dysfunctioning of GPCRs is associated with a large number of human diseases, with
almost half of currently available drugs targeting GPCRs. 2
GPCR signaling occurs via the binding of an extracellular ligand to the receptor’s
N-terminus, causing a conformational change, which, in turn, allows the intracellular Cterminal domain to interact with proteins in the cytosol. 1 In classical GPCR signaling,
the intracellular domain of the receptor couples to a membrane-bound heterotrimeric G
protein. 3 G proteins are guanine nucleotide-binding proteins that bind GDP in their
inactive form and release GDP upon coupling to GPCRs, which causes binding of GTP in
its place. 4 The binding of GTP initiates propagation of signaling through G protein
activation of effector proteins. G proteins contain α, β, and γ subunits, and their multiple
subfamilies are typically defined by the isoform combination of the α and βγ dimer

1

subunits, with each combination interacting with different effector proteins to initiate

2

different cellular signaling pathways. 5

Figure 1. Classical “G Protein-Dependent” GPCR Signaling. Coupling of the ligandbound receptor to an inactive G protein causes a conformational change in the α subunit,
resulting in the release of GDP. Binding of GTP to the α subunit causes dissociation of
the α subunit from the GPCR and from the βγ dimer. Each component is now activated
and capable of activating effector proteins.
CXCR4
CXCR4 is a GPCR that functions as a chemokine receptor. Chemokines are
signaling peptides secreted by cells, which act as local mediators of cell-cell
communication, with their most classic function being to chemically attract cells to
migrate in certain directions (known as chemotaxis). 6 CXCR4 is important in various
cellular signaling pathways involved in embryogenesis, in the development of the heart,
brain, and vasculature. 7, 8 It is important, non-embryonically, in stem cell homing to the
bone marrow during hematopoiesis and mediation of immune cell trafficking in
inflammation. 9, 10 CXCR4 is also involved in immune cell invasion, cell adhesion, cell
survival, angiogenesis, and tissue repair mechanisms. 11
CXCR4 Signaling
CXCR4 binds almost exclusively to the C-X-C Ligand 12 (CXCL12, which is
sometimes referred to as SDF-1). Binding of CXCL12 to CXCR4 initiates signaling

pathways in the cell that mediate cell migration, adhesion, survival, and proliferation

3

processes. 12
CXCR4 most often couples with Gi proteins. 13 Activation of the Gαi subunit
inhibits adenylyl cyclase, resulting in a decrease in the intracellular level of the second
messenger cyclic adenosine monophosphate (cAMP). Activated Gαi subunits can also
activate Src proteins. In addition, the activated βγ dimer in the CXCR4 G proteindependent pathway can contribute to activation of AKT signaling by activating PI3K
(Phosphoinositide 3-Kinase). 13
Another example of CXCR4 signaling occurs through the binding of β-arrestin
proteins to activated CXCR4, which act as signaling scaffolds that interact with
downstream effector proteins of various signaling pathways. 14 In particular, a complex
formed between β-arrestin-1 and STAM-1 proteins with CXCR4 on endosomal
membranes has been shown to be involved in promoting autophosphorylation of FAK
(focal adhesion kinase) proteins in response to CXCR4 activation, leading to cell
migration. 15 In addition, disrupting this interaction was shown not to disrupt activation of
ERK1/2 or AKT signaling through G protein coupling.

4

Figure 2. CXCR4 G Protein-Dependent Signaling Cascade. 16 Some of the known
signaling pathways that are mediated by the actions of CXCR4 include such functional
cellular outcomes as proliferation, migration, and survival.
CXCR4-Related Disease States
It was first realized that CXCR4 was pathologically involved in disease when it
was discovered that HIV utilized CXCR4 as a co-receptor to invade helper T-cells. 17
CXCR4 has since been found to be involved in a number of other diseases including
cardiovascular disease, WHIM (Warts, Hypogammaglobulinemia, Immunodeficiency,
and Myelokathexis) syndrome, and cancer. A major component of the pathology of
disease states involving CXCR4 is a dysregulation of CXCR4 expression.
In particular, CXCR4 overexpression is seen in at least 23 different types of
cancer. This is not entirely surprising considering the developmental, homeostatic, and
migratory roles that CXCR4 signaling can play in certain healthy tissues, an over
activation of which would be, assumingly, beneficial to tumor growth and malignancy. 18

Evidence of this exists in that CXCR4 has been shown to mediate adhesion of cancer

5

cells to stromal cells stimulating tumor cell proliferation, migration, invasion, survival,
and neoangiogenesis. 19-24
Interestingly, CXCR4 overexpression has also been shown to play an important
role in the metastasis of cancer, in that certain tissues constitutively expressing CXCL12,
such as the bone marrow, lung, liver, and brain, can cause cancer cells overexpressing
CXCR4 to home to and invade these tissues as a result of CXCL12 signaling. 25 A
specific example of CXCR4 overexpression playing a role in metastasis can be seen in
breast cancer cells, where the CXCR4/CXCL12 signaling axis can mediate actin
polymerization, resulting in the formation of pseudopodia and increased potential for
chemotaxis and metastasis of breast cancer cells. 26
CXCR4 Antagonists as Therapeutics
There has been an effort to utilize CXCR4 antagonists in the treatment of certain
cancers, however the only drug that is currently approved by the FDA is Plerixafor (Also
known as Mozobil and AMD-3100). Plerixafor was first developed for treatment of HIV,
but this was abandoned because it was not effective against M-tropic CCR5 HIV strains,
and because of its poor oral bioavailability. 27 However, Plerixafor eventually received
approval by the FDA for use in combination with granulocyte colony-stimulating factor
(GCSF) to mobilize hematopoietic stem cells to the bloodstream in order to be collected
and transplanted autologously into patients with Non-Hodgkin’s Lymphoma and Multiple
Myeloma. 28
Some of the side-effects from Phase I/II trials that Plerixafor underwent for antiHIV uses included increase in white blood cells, and cardiac arrhythmia. 29

Overproduction of white blood cells, or hyperleukocytosis, is dangerous because it
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results in increased blood viscosity and hematological stasis, and can predispose patients
to neurological and gastrointestinal complications. However, use of Plerixafor combined
with GCSF in Phase I-III clinical trials demonstrated that it had minimal side-effects, in
part because of its relatively short time-frame of administration needed to mobilize stem
cells when compared to the time-frame of administration needed in treatment of HIV. 30
It has also been attempted to use CXCR4 antagonists against multiple types of cancers,
however none, as yet, have achieved FDA approval for such use.
The use of CXCR4 antagonists in the prevention of cancer metastasis is of great
interest due to the known role of the CXCR4/CXCL12 signaling axis in homing of
malignant cells to secondary tissues. T140 analogs are short peptide CXCR4 antagonists
that have been shown to effectively reduce metastasis in addition to primary growth of
breast cancer in mouse models. 31 However, to date, neither T140 analogs, nor any other
class of CXCR4 antagonists, have been approved by the FDA for such use, which is not
wholly surprising considering the known side-effects that can occur when administering
CXCR4 antagonists in humans. Thus, there is a clear need for novel therapeutic agents
that target downstream effectors involved in the mediation of CXCR4 expression and/or
migration-related signaling (FAK), which can potentially disrupt the ability of malignant
cells to migrate without disrupting the other signaling pathways that are necessary for
homeostatic functions in healthy cells.
CXCR4 Regulation
The clinical relevance of CXCR4 overexpression in disease states makes the
understanding of the manner in which CXCR4 levels are regulated in healthy cells of

great importance, as it can give insight into which mechanisms within the pathway can
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potentially be targeted pharmacologically to decrease CXCR4 signaling more effectively
and with fewer side effects.
The natural mechanism for lowering CXCR4 signaling in cells classically occurs
through homologous desensitization of the receptor, which is a rapid, but transient,
inactivation of signaling through the activated receptor. This occurs through a
desensitization process that is typical to GPCRs, where binding of the ligand induces
phosphorylation of the intracellular domain of the receptor by a G Protein Receptor
Kinase (GRK) enzyme. 32 The phosphorylation of the receptor recruits β-arrestin proteins
to bind CXCR4 at the phosphorylated sites, which serves to sterically hinder the
activation of additional G proteins, as well as to recruit proteins that promote
internalization of the receptor onto early endosomes. 32, 33 Removal of CXCR4 from the
cell surface prevents further ligand-mediated activation of signaling through the receptor.
Once internalized, CXCR4 is sorted to one of two pathways. One is a recycling
pathway, through which CXCR4 is trafficked back to the plasma membrane, where it can
undergo another ligand-mediated signaling event in a process called “re-sensitization.” 34,
35

The other pathway that CXCR4 can enter is a degradative pathway, where it is

trafficked to lysosomes via multi vesicular bodies (MVBs) where the receptor is
subsequently degraded. 36 The degradation of CXCR4 causes its signal to be attenuated
and prevents the receptor from undergoing additional ligand-mediated signaling events,
causing longer-term “downregulation” of CXCR4 signaling.
Knowing this mechanism of regulation provides a potential target for adjusting
the balance between the recycling and degradation pathways in order to modulate the

magnitude of receptor expression. For instance, it has been shown that interrupting the
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interactions between β-arrestin-1 and STAM-1 proteins in HeLa cells accelerates
degradation of CXCR4, which could be utilized to influence downregulation of CXCR4
in diseased cells. 37
Endocytosis. CXCR4 can be internalized into cells through a mechanism of
classical, dynamin-dependent endocytosis mediated by β-arrestin. 33 The binding of βarrestin to phosphorylated sites on the intracellular domain of the receptor causes a
conformational change in β-arrestin, allowing it to bind clathrin and AP2 proteins that
cause endocytosis of the receptor via clathrin-coated pits. 38 There is evidence, however,
that CXCR4 is also capable of undergoing endocytosis in a β-arrestin-independent
mechanism. 39
Endosomal Sorting. Once endocytosed, CXCR4 receptors localize onto early
endosomes. The early endosome is a sorting station within the cell where different posttranslational modifications and protein interactions determine whether CXCR4 will be
shuttled into the degradative pathway or be recycled back to the plasma membrane for
further signaling.
The majority of CXCR4 is shuttled into the degradative pathway in response to
CXCL12 stimulation. 13 However, a small amount of receptors are recycled back to the
membrane via Rab-11-positive recycling endosomes. 40
Ubiquitination of CXCR4 by the Atropin-1-Interacting Protein 4 (AIP4) shortly
after binding CXCL12 is a post-translational modification that helps direct CXCR4 into
the degradative pathway. 36, 41 This occurs through interactions with the Endosomal
Sorting Complexes Required for Transport (ESCRT) machinery, which functions to

concentrate the ubiquitinated receptor into clathrin-coated pits within the endosomal
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membrane that pinch off to form intraluminal vesicles (ILVs) within multi vesicular
bodies (MVBs) (Figure 3). 42 The MVBs subsequently fuse with lysosomes, leading to
the degradation of the receptor.
Interaction of β-arrestin-1 with CXCR4 on the endosomal membrane also plays
an important role in the mediation of CXCR4 trafficking to the lysosome. It has been
shown that β-arrestin-1 can act as a positive regulator of CXCR4 degradation, since
siRNA knockdown of β-arrestin-1 causes a decrease in the degradation of CXCR4. 43
However, it has also been shown that interaction between β-arrestin-1 and a subunit of
the ESCRT-0 protein serves to negatively regulate the rate at which CXCR4 is shuttled
into the degradative pathway. ESCRT-0 is a protein complex consisting of two subunits
known as HRS and STAM-1. It has been shown that a ubiquitin-interacting motif (UIM)
on HRS binds the ubiquitin moiety on CXCR4, and that a direct interaction between βarrestin-1 and the STAM-1 subunit on ESCRT-0 occurs when β-arrestin-1 is recruited to
the receptor on the endosomal membrane. 37, 41 Moreover, it has been shown that this
interaction is responsible for a negative regulatory role of CXCR4 degradation, as
STAM-1 siRNA-mediated disruption of the interaction between these two proteins causes
an attenuation of CXCR4-mediated HRS ubiquitination, and thus enhanced CXCR4
degradation. 37 It is possible that β-arrestin-1 initially directs CXCR4 to ESCRT-0, and
that this is followed by an interaction with STAM-1 that attenuates CXCR4 degradation.
It is thought that the interaction between β-arrestin-1 and STAM-1 serves to modulate the
ubiquitination status of HRS by acting as an adaptor protein for AIP4 to ubiquitinate
HRS, and that a poly-ubiquitination of HRS attenuates the sorting of CXCR4 into the

degradative pathway. This is thought to occur through an autoinhibitory interaction
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between the ubiquitin moiety added to HRS and its own internal UIM. This causes HRS
to dissociate from the receptor and prevents recruitment of the remaining ESCRT
machinery, thus preventing budding of the receptor from the endosomal membrane into
ILVs. Occasionally, the interaction between ESCRT-0 and CXCR4 is able to remain
stable for long enough to allow the remaining components of the ESCRT machinery
(ESCRTI-III) to be recruited to the receptor on the endosomal membrane, initiating
budding of the receptor into ILVs. Thus, the interaction between β-arrestin-1 and STAM1 serves to slow the process of lysosomal degradation of CXCR4 that normally occurs
very easily, and it is conceivable that interrupting these interactions would accelerate the
lysosomal degradation of CXCR4.

11

Figure 3. CXCR4 Homologous Desensitization Pathway. CXCR4 enters either a
recycling or a degradative pathway. The interaction between STAM-1 and β-Arrestin-1
facilitates a negative regulatory mechanism causing ESCRT-0 to dissociate from the
receptor and preventing the recruitment of further ESCRT machinery.
To date, the interaction between β-arrestin-1 and STAM-1 has not been shown to
take part in the trafficking of any other receptors besides the endosomal sorting of
CXCR4. It has been shown that the interaction is not involved in EGFR degradation (an
RTK known to interact with ESCRT-0 as part of its endosomal sorting process), as its
degradation was unaffected by the expression product of a minigene (β-arrestin-1 “25-

161”) that acts as a competitive inhibitor of STAM-1/β-arrestin-1 binding. 37 Further,
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it has been shown that STAM-2 is not involved in the endosomal sorting of CXCR4. 37
Bioluminescence Resonance Energy Transfer (BRET)
Because it has been shown that the disruption of the interaction between βarrestin-1 and STAM-1 can cause accelerated degradation of CXCR4, and because this
would be desirable in diseased cells that have an overexpression of CXCR4, there is
motive to design an assay with which the status of the interaction between these two
proteins is indicated. This assay could then be used to search for small molecules that
have the ability to disrupt this interaction.
Certain proteins possess the ability to absorb light energy at certain wavelengths,
causing their electrons to become excited in such a way that when the electrons
eventually relax to their ground state, light energy is released at a wavelength within the
visible spectrum. 44 This phenomenon is known as fluorescence. Some fluorescent
proteins emit fluorescence energy at a wavelength that is capable of causing excitation of
other fluorescent proteins, after which they emit their own wavelength of fluorescence.
This phenomenon is known as resonance energy transfer (RET) and can occur in cells
when the two expressed fluorescent proteins are within 10-100Å of one another. 45
This phenomenon can be utilized to study protein-protein interactions in live cells
by genetically fusing the two fluorescent proteins separately to two different proteins of
interest that are thought to interact in the cell. Typical interactions between proteins are
sufficient to bring the fluorescent proteins in close enough proximity for RET to occur.
Therefore, light of a specific wavelength can be shone onto cells expressing the two
fusion proteins to cause the “donor” moiety to become excited and, if the two proteins are

interacting, RET will occur and a fluorescence will be observed at the wavelength
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characteristic to the “acceptor” moiety. This technique is known as Fluorescence
Resonance Energy Transfer (FRET). 46
A major disadvantage of FRET is that shining light onto the cells to cause
excitation of the donor moiety can cause photobleaching, decreasing the signal:noise ratio
and making the assay less sensitive to the level at which the proteins are interacting with
one another. 47 Another disadvantage to FRET is that the wavelength at which the two
fluorescent moieties become excited is a range rather than one wavelength, and shining
light on the cells can cause transient excitation of the acceptor moiety, leading to false
positive readings if the excitation spectrum of the acceptor moiety is close to that of the
donor moiety.
Certain proteins, however, are capable of undergoing reactions with certain
chemical substrates that cause the same type of electron excitation and light energy
emission that is seen in fluorescence. Light energy that is released as a result of this type
of chemical excitation is called bioluminescence, and can be utilized in the same way to
study protein-protein interactions. This can be carried out by replacing the donor moiety
from FRET with a bioluminescent moiety, and adding the substrate that causes excitation
of the bioluminescent moiety to the cells in order to initiate RET. 48 This technique is
referred to as Bioluminescence Resonance Energy Transfer (BRET). One of the main
advantages of this technique is that the chemical reaction eliminates the need for light
excitation and thus, eliminates the possibility of photobleaching, making the assay much
more sensitive to small amounts of light emission.

The majority of BRET experiments utilize a bioluminescent protein (Rluc)
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found in the Renilla Reniformis sea pansy that endogenously reacts with a protein called
coelenterazine to emit bioluminescence. 49 The first form of experimental BRET
developed, referred to as BRET1, utilizes a humanized derivative of coelenterazine to
react with Rluc causing bioluminescent emission at a wavelength of ~470 nm. In BRET1
Rluc is paired with a yellow fluorescent protein (YFP) acceptor that absorbs the light
emitted at ~470nm and emits yellow fluorescent light at ~530nm. 48 A further optimized
form of BRET (BRET2) utilizes another modified derivative of coelenterazine, known as
DeepBlueC©, which causes Rluc to emit light at 400 nm. 50 In BRET2 Rluc is paired
with a green fluorescent protein (GFP) acceptor, which absorbs the light emitted by Rluc
at 400nm and emits green fluorescent light at 510nm. The advantage of BRET2, when
compared to BRET1, is that it yields a better spectral emission (the difference between
donor and acceptor emissions) and increases the signal:noise ratio of measurements
taken. BRET1, however, has the advantage that a longer reaction duration occurs between
Rluc and coelenterazine(h) (~1 hour) when compared to a reaction duration of only few
minutes for DeepBlueC©. Evidence of these fluorophores successfully yielding a quality
BRET signal when fused to two proteins that are related to this project can be seen in a
recent study that utilized CXCR4-Rluc and β-arrestin2-GFP fusion proteins. 51
BRET experiments typically use a plate reader to measure both the
bioluminescence emission level of Rluc as well as the fluorescence emission level of the
fluorescent acceptor. This is due to the fact that any bioluminescence emission is a result
of Rluc not being in close enough proximity to the fluorescent moiety for it to absorb the
energy, and therefore the level of bioluminescence emission measured is indicative of the

level at which the two proteins of interest are not interacting. This measurement can be
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used in conjugation with the amount of fluorescence measured in order to quantitatively
calculate the level at which the proteins are interacting in the cell by calculating a “BRET
Ratio.” A BRET ratio is simply the measured level of fluorescence divided by the level of
measured bioluminescence. 47

Figure 4. Bioluminescence Resonance Energy Transfer (BRET). (a) Graphical
representation of the phenomenon of bioluminescence. (b) A graphical representation of
interactions that allow BRET2 measurements to be made. A similar interaction occurs in
BRET1, however DeepBlueC is replaced by coelenterazine(h), GFP is replaced with YFP,
and different emission wavelengths occur.
The BRET technique as described above is an attractive assay with which to
monitor the interaction between β-arrestin-1 and STAM-1 because it allows monitoring
of these interactions in live cells and it provides a high signal to noise ratio, when
compared with other assays. To develop this assay, Rluc and either YFP or GFP moieties
need to be fused to either protein in an appropriate location so as not to disrupt the
normal ability of these proteins to interact with one another.
β-Arrestin-1
There exist two isoforms of β-arrestin, β-arrestin-1 and β-arrestin-2. They are
known as the “non-visual” arrestins, because both are found ubiquitously throughout all

human cell types, unlike the rhodopsin-like isoforms found in rod and cone cells

16

(known simply as arrestins). In general, β-arrestin-1 and β-arrestin-2 differ with respect
to CXCR4 signaling, however, in that β-arrestin-2 is involved in the internalization of the
receptor, whereas β-arrestin-1 is more involved in endosomal trafficking. 33, 43 It has been
established that both isoforms interact with phosphorylated residues on receptors via
positively charged amino acids near their N-terminus. 52 Therefore, it is logical that any
fusion protein made of β-arrestin should contain the attached moiety within either the Cterminus or somewhere in the middle of β-arrestin’s amino acid sequence.
STAM-1
As stated previously, STAM-1 is the protein within the ESCRT-0 protein complex
that binds β-arrestin-1 in the endocytic trafficking of CXCR4. STAM-1 can also exert
signaling functions, nevertheless, this project will focus on its role as a negative regulator
of CXCR4 degradation. STAM-1 differs from the other STAM isoform, STAM-2, with
respect to the fact that they traffic different receptors, with STAM-1 being specific to the
trafficking of CXCR4. 37 Moreover, it has been shown that STAM-1 interacts
specifically with β-arrestin-1 and not β-arrestin-2, as interactions between STAM-1 and
β-arrestin-2 were not detected in co-immunoprecipitation experiments. 37
STAM-1 contains a “coiled-coil” region (CC) in the middle of its amino acid
sequence where, binding sites for β-arrestin-1 and HRS exist. 37, 53 STAM-1 contains an
immunoreceptor tyrosine-based activation motif (ITAM) that binds JAK proteins, and an
SH3 domain, where an AIP4 binding site and other signal transduction sites are located.
54, 55

Finally, STAM-1 contains a VHS domain and an adjacent ubiquitin interacting

motif (UIM) containing ubiquitin binding sites that are associated with interactions

between STAM-1 and regulatory molecules that are involved in the sorting of proteins
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in the MVB pathway, such as de-ubiquitinating enzymes (DUBs). 56

Figure 5. STAM-1 Functional Domains. Schematic of domains within STAM-1 and
their locations in its primary structure.
Project Rationale and Research Objectives
Disruption of CXCR4 signaling in diseased cells overexpressing CXCR4 by
administration of CXCR4 antagonists in humans causes various side effects, thus, a novel
approach must be considered in order to improve the efficacy of such drug treatments,
while simultaneously reducing these side-effects. A more effective way to approach this
problem is to search for drugs that target downstream effectors in either the
recycling/degradation pathway of CXCR4 or in migration-related signaling pathways.
The interaction between STAM-1 and β-arrestin-1 is a good candidate for targeted
therapy since it has been shown that disruption of this interaction causes an increase in
CXCR4 degradation. Moreover, disruption of this interaction has also been shown to
significantly reduce FAK autophosphorylation and prevent cell migration without
affecting other signaling pathways such as ERK and AKT. Thus, targeting the interaction
between STAM-1 and β-arrestin-1 is a novel approach to reducing upregulated CXCR4
signaling in disease states, which should be pursued for its potential to prevent cancer
metastasis and to be more selective at targeting particular CXCR4 signaling pathways,
therefore potentially reducing side-effects.

With this goal in mind, the objective of this project is to develop an assay with
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which to monitor the interaction between STAM-1 and β-arrestin-1 in live tumor cells.
This assay could then be used to perform high-throughput screening for potential
inhibitors of this interaction. The identified inhibitors would be good candidates for use
as novel therapeutics that target upregulated CXCR4 in diseased cells by both reducing
cell surface expression and selectively inhibiting migration-related signaling. Such drugs
could significantly reduce cancer metastasis by preventing CXCL12-mediated tumor cell
migration, with fewer side effects.

CHAPTER 2
MATERIALS AND METHODS
Reagents
A list of all reagents and buffers used in this project, including all relevant
information and how they were made, is located in Appendix A.
DNA
A summary of all DNA used throughout the course of these experiments,
including all pertinent information, is listed in Table 1 below.
Name:
Vector:
Received From:
T7-STAM1-Rluc pRluc-N1(h)
T7-STAM-1
pCMV10
pRluc-N1(h)
N/A
BioSignal Packard
β-Arrestin1-mYFP
pcDNA3.1
Addgene
β-Arrestin1-GFP
pCMV10
Trejo Lab
CXCR4-Rluc3
hRluc-N3
Heveker Lab
pEYFP-C1
N/A
Clontech
pCMV10
N/A
Sigma
pcDNA3
N/A
Clontech
Table 1. DNA Used in Experiments.

Reference:
Reported Here
Malik and Marchese, 2010
Joly et al, 2001
Violin et al, 2006
Lin and Trejo, 2013
Percherancier, 2005
Bhandari, D. 2007
-

Construction of T7-STAM1-Rluc Fusion Protein Expression Plasmid
T7-STAM-1 DNA that had been constructed by a previous lab member was
cloned into the multiple cloning site (MCS) of a BRET2TM codon humanized Rluc fusion
protein expression vector (pRluc-N1(h); BioSignal Packard, Montreal, Quebec) such that
the Rluc sequence would be located at the 3’ (expressed at the C-Terminal) end of the
T7-STAM-1 sequence. 37
19

Primers. Custom primers (Forward: 5’-ATATAAGCTTAGCTATGGCTAG
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CATGACTGGTG-3’ Reverse: 5’-ATATGGGCCCTAGCAGAGCCTTCTGAGAATA
TG-3’) were ordered from Eurofins Genomics and were received as ~500µg lyophilized
pellets, which were resuspended in ~500µL of nano-purified water to produce 100µM
stock solutions. From each of these, 20µL was diluted in 80µL nano-purified water to
yield 20µM working solutions.
PCR. PCR was performed using the Expand High Fidelity PCR System (Roche).
Sequentially, nano-purified water, 10X Expand High Fidelity PCR buffer containing
15mM MgCl2, each 20µM primer, 100ng/µL T7-STAM-1 DNA, 10mM dNTP solution,
and Taq polymerase were added to a PCR tube in the volumes listed in Table 2. The
reaction was then run in a GeneAmp® PCR system thermocycler (Model 9700; Applied
Biosystems) under the conditions shown in Table 3.
Reagent
H2 O
PCR Buffer
S1-Luc-HindIII-F
S1-Luc-ApaI-R
T7-STAM-1 DNA
dNTP
Taq Polymerase
Total:

Volume
28µL
5µL
2µL
2µL
10µL
2µL
1µL
50µL

Table 2. PCR Reagents and Volumes.
Phase
Denaturing
Annealing
Extension
# Cycles
Holding
Table 3. PCR Reaction Conditions.

Temperature
94˚C
50˚C
72˚C

Time
1min
1min
2min
30

4˚C

-

Gel Verification and Extraction. The PCR product was visualized by adding
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15µL 6X loading dye (Qiagen) and 5µL of 10mg/mL ethidium bromide to 50µL of PCR
product sample and subjecting it to electrophoresis on a 1% agarose gel (1g agarose in
100mL 1X TAE buffer) at 130V for 1 hour with a 10 Kb ladder (Promega). The gel was
then viewed under UV light using a Fisher Scientific UV light box (Figure 7, Chapter 3).
The band resulting at approximately 1.6 Kb was cut from the gel and purified using a
Qiagen QIAquick Gel Extraction kit, according to the manufacturer’s protocol. The
concentration of this product was determined using a Nanodrop 8000 spectrophotometer
apparatus (Thermo Scientific).
Restriction Enzyme Digestion. The PCR product (Insert) and pRluc-N1 (Vector)
were separately combined in Eppendorf tubes with 10µg/µL ApaI restriction enzyme
(Promega), 10x Promega Buffer A, 10mg/mL BSA, and nano-purified water in volumes
corresponding to those listed in Table 4 and incubated at 37˚C for 1 hour.
Reagent
Vector
Insert
H2 O
18.5 µL
13.5 µL
Buffer A
5 µL
5 µL
BSA
0.5 µL
0.5 µL
ApaI
1 µL
1 µL
DNA
25 µL
30 µL
Total Volume =
50 µL
50 µL
Table 4. ApaI Digest Reagents and Volumes. Volumes shown for separate digest
reactions of the pRluc-N1 vector and the PCR product insert.
The products of the ApaI digestion were purified using a Qiagen PCR purification
kit according to the manufacturer’s protocol, and the concentrations were measured using
a Nanodrop 8000 spectrophotometer (Thermo Scientific). Purified DNA from each
digestion was then combined in separate Eppendorf tubes with 10µg/µL HindIII
restriction enzyme (Promega), 10x Promega Buffer E, 10µg/µL BSA, and nano-purified

water in volumes corresponding to those listed in Table 5 and incubated at 37˚C for 1
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hour.
Reagent
Volumes for Both Digestions
H2 O
0.7 µL
Buffer E
3 µL
BSA
0.3 µL
HindIII
1 µL
DNA
25 µL
Total Volume =
30 µL
Table 5. HindIII Digest Reagents and Volumes. Volumes shown for both digest
reactions run separately with each product from ApaI digestion.
Ligation. The products of the HindIII digestion were purified using the same
Qiagen PCR Purification kit mentioned previously, and their concentrations were
determined using a Nanodrop 8000 spectrophotometer (Thermo Scientific). The purified
DNA was then combined separately at a 1:1 and 1:3 ratio of vector to insert. Ligation of
the insert into the vector was carried out by addition of nano-purified water, 10X T4
ligation buffer (Promega), and T4 DNA ligase (Promega) in volumes corresponding to
those listed in Table 6, and incubated at 4˚C overnight.
Reagent
1:1
H2 O
3 µL
Insert DNA
7 µL
Vector DNA
7 µL
Ligation Buffer
2 µL
Ligase
1 µL
Total Volume =
20 µL
Table 6. Ligation Reaction Reagents and Volumes.

1:3
1 µL
12 µL
4 µL
2 µL
1 µL
20 µL

Transformation of Bacteria. 50µL of competent DH5α-F’ E. coli cells (in
100mM CaCl2 and 15% glycerol) were inoculated separately with 3µL of each ligation
product. The samples were incubated for 30 minutes on ice, heat shocked in a 42˚C water
bath for 2 minutes, and cooled on ice for a further 2 minutes. 600µL of LB broth was

added to each sample, which were then incubated at 37˚C for 30 minutes. The
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transformed cells were then centrifuged at 3000 rpm for 3 minutes and the resulting
supernatant was carefully aspirated such that approximately 100µL remained, and the
solution was mixed to dissolve the pellet. The samples were then seeded onto LB agar
plates containing 25mg/mL kanamycin (Appendix A), two for each insert to vector ratio
that were divided into 100µL and 50µL volumes. The plates were incubated for
approximately 18 hours at 37˚C. 10 colonies were randomly selected from the plates and
individually inoculated into 5mL of LB broth containing 10µL of 25mg/mL kanamycin
(Sigma) and incubated overnight in a 37˚C orbital shaker. The following day, DNA was
purified from each sample using a Promega PureYield Plasmid miniprep kit.
Screening for Inserts. Purified plasmids were digested with ApaI and HindIII
(combined with the reagents listed in Table 7) according to the protocol described for the
previous digestion reaction.
Reagent
Volume
H2 O
6.8 µL
Digestion Buffer
2 µL
BSA
0.2 µL
E. Coli Culture
10 µL
ApaI
0.5 µL
HindIII
0.5 µL
Total =
20 µL
Table 7. T7-STAM1-Rluc Diagnostic Restriction Digest Reagents and Volumes.
Each sample was then purified using a Promega PureYield Plasmid miniprep kit
and subjected to electrophoresis on a 1% agarose gel and viewed under UV light using a
Fisher Scientific UV light box to determine if any of the transformations were successful.
The sample corresponding to lane 2 (Figure 8, Chapter 3) was selected and the bacterial
culture that it was grown in was inoculated into 250mL of LB broth in order to prepare a

working solution of DNA, according to the large scale DNA extraction protocol
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described below.
DNA Sequencing. The remaining purified DNA (~20µL) was sent to be
sequenced by ACGT company (Wheeling, IL). The results of the sequencing analysis
confirmed that the identity of the cloning product was the desired T7-STAM1-Rluc, as
represented in the nucleotide and amino acid sequence and plasmid map displayed in
Figures 9 and 10 (Chapter 3).
Large Scale DNA Extraction
All large scale working DNA solutions used in these experiments were prepared
using the following protocol. DH5α-F’ E. coli cells are transformed with the desired
DNA by pipetting 100µL of the competent cells into an Eppendorf tube and adding 1µL
of the DNA to be prepared. The cells are incubated on ice for 30 minutes and then heat
shocked in a 42˚C water bath for 2 minutes. The cells are then placed back on ice and
incubated for 2-10 minutes. 600µL of LB broth is then added and the tubes are incubated
at 37˚C for at least 20, but never longer than 60, minutes. 50µL of the cells are then
seeded on an LB agar plate containing 25µg/µL kanamycin or 50µg/µL ampicillin,
corresponding to the resistance gene contained in the plasmid of interest. Plates are then
placed upside down in a Precision incubator and incubated at 37˚C overnight.
The following day, an isolated colony is selected from the plate using an
inoculating loop and inoculated in 5mL of LB broth containing 25µg/µL kanamycin or
50µg/µL ampicillin in a 15mL round-bottomed Falcon tube and placed into an orbital
shaker for 7 hours at 250 rpm and 37˚C. The bacterial suspension is then used to
inoculate 250mL of LB broth in a 1L flask containing 100mg/mL antibiotic, which is

placed into an orbital shaker at 250 rpm and 37˚C for approximately 18 hours. The
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DNA of interest is then isolated from the bacterial cells using a Qiagen HiSpeed Plasmid
Maxi kit according to the manufacturer’s instructions.
Cell Lines Used
HeLa human cervical cancer cell lines (obtained from American Type Culture
Collection; Manassas, VA; Cat: CCL-2; Lot: 63226283) were maintained in Dulbecco’s
Modified Eagle Medium – High Glucose (DMEM; Sigma-Aldrich, St Louis, MO; Cat:
D5796) containing L glucose, L-glutamine, and sodium bicarbonate, supplemented with
10% fetal bovine serum (FBS; Sigma-Aldrich; Cat: F0926; Batch: 16A164) in a
humidified atmosphere at 37˚C and 5% CO2.
Transfection of DNA
Transfection of DNA was performed with cells that had been cultured in either
10-cm or 6-well plates using polyethylenimine (PEI) in a biological safety cabinet to
maintain sterility. For these experiments, cells were typically 90-100% confluent at the
time of transfection.
Transfections were performed by aliquoting appropriate amounts of DNA for
each transfection condition into Eppendorf tubes, to which 500µL of Opti-MEM (Gibco,
Grand Island, NY) is added, and the solution is incubated at room temperature for 5
minutes. Additionally, a stock solution of PEI (Polysciences, Inc., Warrington, PA) at a
concentration of 1mg/mL in 30% ethanol (Sigma-Aldrich) is aliquoted into Opti-MEM at
a ratio of 20µL PEI to 500µL Opti-MEM for each transfection condition, and incubated
at room temperature for 5 minutes. This solution is then pipetted into the DNA/OptiMEM solution and the mixture is incubated for 15 minutes at room temperature to allow

for complex formation. The solution is subsequently added drop-wise to cell cultures
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and incubated overnight at 37˚C and 5% CO2.
Co-Immunoprecipitation
Co-immunoprecipitation was performed in HeLa cells transfected with 5µg of T7STAM1-Rluc DNA and 5µg β-arrestin1-GFP DNA grown in 10cm tissue culture plates,
according to the protocol outlined above. After 24 or 48 hours, transfected cells were
harvested on ice by aspirating the media, washing the cells once with cold Dulbecco’s
Phosphate Buffered Saline (DPBS; Sigma-Aldrich) solution, and scraping the cells in
500mL (for 10cm plates) of Co-Immunoprecipitation buffer (50mM Tris HCl (pH 7.5),
150mM NaCl, 0.5% NP-40, and 10µg/mL each of Aprotinin, Pepstatin A, and
Leupeptin). Cells from each transfection condition were transferred into individual
Eppendorf tubes and placed on a rocker at 4˚C to allow the cells to solubilize. Each
solution was sonicated at 11% for 10 seconds on ice, and cleared cell lysates were
generated by centrifugation at 14,000 rpm and 4˚C for 30 minutes. The resulting
supernatant was carefully transferred to a clean Eppendorf tube. The concentration of the
cleared lysate was then determined using a PierceTM BCA Protein Assay Kit (Thermo
Scientific, Rockford, IL) according to the manufacturer’s instructions, and read at 562nm
on a PowerWaveX 340 (Bio-Tek Instruments, Inc., Winooski, VT). The concentrations
were then equalized to the lowest protein concentration by addition of Co-IP buffer. An
aliquot from each of the adjusted samples representing input was saved in a fresh
Eppendorf tube with an equal volume of 2X sample buffer (Apendix A; 8% SDS, 10%
Glycerol, 0.7M β-mercaptoethanol, 37.5mM Tris HCl pH 6.5, 0.003% bromophenol
blue) and stored at -20˚C. 1µL of the IP antibody (T7 goat) was added to remaining

samples, which were left rocking at 4˚C overnight. The following day 10µL of a 50%
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slurry of protein-A agarose beads (Roche Diagnostics, Indianapolis, IN) equilibrated with
Co-IP buffer, was added to each sample and rocked at 4˚C for a further 60 minutes. The
tubes were then centrifuged for 5 seconds at 10,000 rpm, and the supernatant was
aspirated carefully without disrupting the pelleted beads. The beads were then washed
with 750µL of cold Co-IP buffer and re-centrifugation. This wash step was repeated
twice more. After the final wash step, the remaining buffer was aspirated and 20µL of 2X
sample buffer was added to the beads and the samples were boiled in a heat block for 10
minutes at 100˚C to elute the bound proteins. 10µL of each sample, along with 10µL of
each cleared lysate sample was carefully loaded using a microtip onto a 10% acrylamide
SDS-PAGE gel, prepared according to the protocol described below. The samples were
subjected to SDS-PAGE, Western blot transfer, and immunoblot analysis according to
the protocols described below.
Of note, initial co-immunoprecipitation results yielded a significant band present
at the molecular weight of β-arrestin1-GFP in control conditions where β-arrestin1-GFP
was transfected with empty T7-STAM-1 expression vector. It is not expected that βarrestin1-GFP could co-immunoprecipitate with a T7 antibody if T7-STAM-1 proteins
are not present, however, it is well known that β-arrestin proteins have a propensity to
bind non-specifically with immunoglobulin beads. 57 However, substituting the use of
Triton-X100 detergent with a stronger Nonidet-P40 (NP40) detergent in the buffer in
which co-immunoprecipitation was performed reduced this amount of background
binding drastically.

Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE)
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All SDS-PAGE was performed as follows. A Bio-Rad Mini-PROTEAN 3 Cell
system was used to cast an SDS-polyacrylamide gel by combining corresponding
volumes of the reagents listed in Table 8, in the order listed, in a 50 mL conical tube. The
solution was then pipetted between a spacer plate and a short plate up to ½” from the top
of the plate to prepare the 10% acrylamide “running” gel. 60µL of 2-propanol was
pipetted on top of the mixture between the plates in order to level out the top surface of
the resulting gel.
Reagent
Volume
Sterile Filtered H2O
0.9mL
0.75M Tris-HCl pH 8.8
2.5mL
10% SDS
50µL
30% Acrylamide/Bis1.52mL
acrylamide solution (Sigma)
10% APS
30µL
TEMED
5µL
Table 8. 10% Acrylamide SDS-PAGE Running Gel Reagents and Volumes.
After allowing the running gel to polymerize between the plates for
approximately 20 minutes, the 2-propanol was rinsed off using de-ionized water. The
reagents listed in Table 9 were then combined in corresponding volumes in a 50mL
conical tube, in the order listed, in order to prepare the 3% acrylamide “stacking” gel.
The combined reagents were pipetted between the plates, on top of the running gel, and
either a 10- or 15-well comb was inserted.

Reagent
Volume
Sterile Filtered H2O
1.0 mL
0.75M Tris-HCl pH 6.5
250 µL
10% SDS
22.5 µL
30% acrylamide
200 µL
10% APS
25 µL
TEMED
2.5 µL
Table 9. 3% Acrylamide SDS-PAGE Stacking Gel Reagents and Volumes.
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After the stacking gel had been allowed to polymerize (approximately 20
minutes), the combs were gently removed from between the plates and the plates are
placed into a Mini-PROTEAN 3 Electrophoresis Module Assembly (Bio-Rad). The
electrode assembly is then placed into a mini-tank with enough 1X SDS running buffer
(Appendix A) to cover the top of the short plate. The samples to be run are then carefully
loaded using a microtip into the wells created by the comb in the stacking gel. After the
samples are loaded the mini-tank is filled completely with 1X SDS running buffer and the
lid is placed on top of the assembly connecting the red and black leads to corresponding
ends of the electrode assembly. The electrical leads are plugged into a Thermo Scientific
EC105 electrophoresis power supply and the apparatus is run at approximately 157 volts
for 1 hour.
Western Blot Transfer
Protein samples resolved by SDS-PAGE were transferred by Western blot onto
0.45µm nitrocellulose membranes (GE Healthcare). This was done by, first, removing the
gel from between the two plates that have been removed from the Electrophoresis
Module assembly, and equilibrating it with 1X transfer buffer (Appendix A). Secondly,
the gel is then assembled into a “sandwich” with the nitrocellulose membrane in a MiniTrans-Blot® Electrophoretic Transfer Cell apparatus (Bio-Rad) according to the

manufacturer’s instructions. This assembly is then connected to the electrophoresis
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power supply and run at approximately 100V for 1 hour in 1X transfer buffer.
Immunoblot Analysis
Nitrocellulose membranes containing the transferred proteins were removed from
the transfer apparatus and blocked in a 5% non-fat milk solution in Tris-buffered saline
(20mM Tris-HCl pH 7.5, 150mM NaCl) containing 0.05% TWEEN-20 (TBST) for 30
minutes at room temperature while rocking in order to prevent antibodies from binding to
proteins non-specifically in the membrane. Subsequently the membranes were probed for
the presence of certain proteins by incubation in solutions of 5% non-fat milk in TBST
with a specific antibody overnight. The following day the membranes were washed three
times for 5 minutes with TBST. After washing, the membranes were incubated in a
solution of 5% non-fat milk in TBST containing horseradish peroxidase (HRP)conjugated secondary antibody for 30 minutes at room temperature while rocking.
Following incubation, the membrane was washed with TBST, once for 5 minutes and
four times for 10 minutes.
Proteins were visualized by incubating the membrane in enhanced
chemiluminescence (ECL) reagent (DURA extended duration substrate, Thermo
Scientific) and placing it into a Bio-Rad Chemi-DocTM Touch Imaging System. This
machine was used to take various images of the membrane using the chemiluminescence
application at various exposure times.
Antibodies Used
All antibodies used in the experiments throughout this project are listed in Table
10 including all pertinent information.
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Name
Type
Vendor
Cat. #
Anti-T7
Goat polyclonal
Abcam
ab9138
Anti-GFP
Mouse monoclonal
Proteintech
66002-1-lg
Anti-STAM-1
Rabbit polyclonal
Proteintech
12434-1-AP
Table 10. Antibodies Used in this Project. Includes animal each was obtained from, as
well as the vendor from whom it was purchased, and corresponding catalogue number.
BRET
In general, all BRET experiments were performed according to the following
protocol, unless otherwise stated. To begin, cells in 10cm plates were transfected with
fusion protein DNA, according to the DNA transfection protocol described above.
Plating of Transfected Cells in 96-Well Plates. The following day, cells were
washed with 10mL of DPBS (Sigma-Aldrich) and detached using 2mL of 0.05% trypsinEDTA (1X; Gibco) for 5 minutes at 37˚C, 5% CO2. 4mL of DMEM supplemented with
10% FBS was then added to each dish, the cells were fully resuspended, and each
solution was transferred into separate 15mL Falcon tubes for each transfection condition.
20µL of each solution was then transferred into separate Eppendorf tubes and the number
of cells in each sample was counted using a BioRad TC10 Automated Cell Counter. The
remaining cell suspensions were centrifuged at 1000xg for 2.5 minutes to pellet the cells
and the supernatant is removed by aspiration. The number of cells counted in each
Eppendorf tube was then used to calculate the amount of DMEM (supplemented with
10% FBS) needed to achieve a concentration of 300,000cells/0.2mL. The calculated
volume was then added, the cells were resuspended by vortexing, and 200µL of cells is
pipetted in triplicate (twice if doing ligand/vehicle stimulation) to wells of a white, clear
bottomed, tissue culture-treated 96-well plate. The plate was then left in a 37˚C, 5% CO2
incubator overnight.

BRET Measurement. The following day the media was carefully aspirated,
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and the cell were washed with 200µL of DPBS containing 0.1% D-glucose twice. 90µL
of DPBS containing 0.1% D-glucose was then carefully added to each well, and if the
cells were to be stimulated with ligand, 90µL 100nM CXCL12 (Protein Foundry,
Milwaukee, WI), or a 100nM BSA (Roche) in DPBS containing 0.1% D-glucose vehicle
solution, were each added to half of the wells corresponding to each transfection
condition. The cells were then incubated for 15 minutes at 37˚C and 5%CO2. A
FlexStation® 3 Multi-Detection Reader with Integrated Fluid Transfer (Molecular
Devices, Sunnyvale, CA) was then used to measure the total fluorescence emission at
530nm in each well following machine excitation at 470nm. White tape was then placed
over the clear bottoms of the wells prior to automated addition of 10µL of 50µM
coelenterazine(h) (Nanolight, Pinetop, AZ) into each well using the FlexStation3 fluidics
module. Luminescence emission at 470nm and 530nm was then measured in each well
for a period of 5 minutes, during which initial luminescence emission magnitudes reach a
peak value. A single “total luminescence” reading was subsequently taken in each well
by selecting “All” wavelengths to be measured in the SoftMax Pro software. A “kinetic”
read of the luminescence emission at 470nm and 530nm was then resumed, and
measurements were taken over an additional 30 to 50 minute period.
BRET Data Analysis. The raw luminescence emission values for each well
obtained from the BRET measurements were exported into an Excel file, and an average
among the three wells for each transfection condition was taken separately for 470nm and
530nm values at each time point. A BRET ratio was then calculated for each transfection

condition at each time point by dividing the luminescence emission at 530nm by the
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luminescence emission at 470nm.
A “Net BRET” value was subsequently calculated for each time point by
subtracting the BRET ratio calculated for the transfection condition containing only T7STAM1-Rluc from the BRET ratio calculated for each transfection condition. In some
cases, the net BRET values from all time points in each transfection condition were
averaged, and these values were further averaged among separate experiments. The
resulting values were then graphed in order to view the corresponding changes in net
BRET seen between the different transfection conditions of the fusion proteins being
studied. Occasionally, only net BRET values obtained from time points where it was
believed that a “relevant” BRET reaction was still occurring were used to calculate the
average net BRET value. A “relevant” BRET reaction was defined as the time points at
which signals that appear to be significantly above baseline readings are being measured.
All graphs presented in this project were generated using GraphPad Prism 6.0
software. The same software was used to perform linear and non-linear regression
analysis of the net BRET values. The “Hyperbola” equation was used as part of the nonlinear regression analysis, which generated a curve fit between data points on net BRET
graphs.
With respect to fluorescence and “total luminescence”, the measured values for
each transfection condition were averaged among experiments. These values were then
standardized by dividing the value from each transfection condition by the value for cells
expressing only the Rluc fusion protein in each experiment. These values from each
transfection condition were then averaged among experiments, and used to graph the

corresponding fluorescence or “total luminescence” value. Error bars representing the
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standard deviation were calculated from the averages among experiments. The error for
the transfection condition in which only Rluc was expressed was calculated by taking the
average of the values among experiments and dividing the value from each experiment
individually by the average. The standard deviation between values was used to generate
the error bars for this particular transfection condition.
These standardized values were also used to calculate [YFP]/[Rluc] values, which
were used as x values in net BRET graphs from BRET experiments between T7-STAM1Rluc and β-arrestin1-YFP.

CHAPTER 3
RESULTS
T7-STAM1-Rluc Expression Plasmid
In order to detect the interaction between β-arrestin-1 and STAM-1 using BRET,
DNA expression plasmids were needed that would express each protein fused to either
GFP/YFP or Rluc. A β-arrestin-1-GFP expression vector was on hand that had been
generously provided by Dr. JoAnn Trejo (UCSD, CA). 58 Therefore, a DNA expression
vector of STAM-1 fused with Rluc needed to be constructed.
A BRET2TM codon humanized Rluc expression plasmid (pRluc-N1(h); BioSignal
Packard, Montreal, Quebec) was used as the cloning vector, which contains a multiple
cloning site (MCS) located at the 5’ end of the Rluc sequence. A mammalian expression
vector of STAM-1 tagged to T7, previously described, was subcloned into the MCS of
pRluc-N1(h) to create a T7-STAM1-Rluc expression vector for T7-STAM-1 with Rluc
fused to its’ C-terminus. 37
Primer Design and PCR. A DNA fragment encoding T7-STAM-1 was amplified
using T7-STAM-1/pcDNA3 as a template by polymerase chain reaction (PCR). Primers
harboring HindIII and ApaI restriction endonuclease sites were designed to facilitate
ligation of the T7-STAM-1 fragment into pRluc-N1(h) in the same reading frame as
Rluc, and to have the stop codon removed (Figure 6; Also included in Figure 9).
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36
S1-Luc-HindIII-F: 5’-ATAT AAG CTT AGCT ATG GCT AGC ATG ACT GGT G-3’
Clamp HindIII
Start
S1-Luc-ApaI-R:

5’-ATAT GGG CCC TAG CAG AGC CTT CTG AGA ATA TG-3’
Clamp
ApaI
Figure 6. Forward and Reverse Primers Designed to Amplify T7-STAM-1. Primers
harboring HindIII and ApaI restriction endonuclease cleavage sites common to MCS in
pRluc-N1(h) designed to facilitate ligation of T7-STAM-1 in frame with Rluc, with
“Start” codon on forward primer to facilitate transcription beginning at T7 tag, and with
“Stop” codon removed on reverse primer to facilitate transcription of Rluc fused to 3’ end
of STAM-1 sequence. Clamp regions inserted next to cleavage sites to facilitate
endonuclease binding.
The PCR product was visualized by 1% agarose gel electrophoresis. The presence
of a band at approximately 1.6 Kb (Figure 7) corresponds to T7-STAM-1.

Figure 7. PCR Amplification of DNA Encoding T7-STAM-1. PCR product was
subject to 1% agarose gel electrophoresis. Band appearing at approximately 1.6 Kb
corresponds to amplified fragment. Molecular weight marker (MWM) in kilobases (Kb)
is shown.
Restriction Digestion, Ligation, and Bacterial Expression. The DNA fragment
was excised from the gel, purified, and subjected to two sequential digestion reactions
with ApaI and HindIII restriction endonucleases. The pRluc-N1(h) plasmid was similarly

digested with ApaI and HindIII to facilitate ligation with the amplified T7-STAM-1
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fragment. The fragment and plasmid were ligated at several molar ratios and transformed
into DH5α-F’ E. coli. Transformants were spread on agar gel plates containing
kanamycin for selection and plated at 37˚C overnight. Colonies were selected for
isolation of small scale plasmid DNA. An aliquot of DNA was digested with HindIII and
ApaI restriction enzymes to determine if T7-STAM-1 had been correctly inserted to
pRluc-N1(h). The resulting digest was visualized by 1% agarose gel electrophoresis, and
it was determined that 3 out of the 10 colonies contained the T7-STAM1-Rluc plasmid,
as indicated by the presence of the plasmid backbone and the 1.6 Kb insert (Figure 8).

Figure 8. Diagnostic Restriction Digest of T7-STAM1-Rluc. Product of ligation
reaction between T7-STAM-1 and pRluc-N1 DNA transformed into E. coli, and DNA
purified from 10 different colonies was subjected to digestion with ApaI and HindIII
restriction enzymes. Products were subject to 1% agarose gel electrophoresis. Bands
appearing at approximately 5 Kb and 1.6 Kb in bacterial samples 2, 3, and 5 are
indicative of successful ligation of T7-STAM-1 DNA into the MCS of pRluc-N1(h).
Sequencing. Purified DNA from bacterial culture 2 was confirmed by sequencing
to be T7-STAM1-Rluc (Figure 9).

Forward Primer
ATATAAGCTTAGCTATGGCTAGCATGACTGGTGà
MCS
HindIII
Start
T7
STAM-1
AGATCTGGAGCTCTCGAGAATTCTCACGCGTCTGCAGGATATCAAGCTTAGCTATGGCTAGCATGACTGGTGGACAGCAAATGGGTCGCGGATCCCCTCT
I W S S R E F S R V C R I S S L A M A S M T G G Q Q M G R G S P L
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<100

TTTTGCCACCAATCCCTTCGATCAGGATGTTGAGAAAGCAACCAGCGAGATGAATACTGCTGAGGACTGGGGCCTCATTTTGGATATCTGTGATAAAGTT
F A T N P F D Q D V E K A T S E M N T A E D W G L I L D I C D K V

<200

GGTCAGTCTCGCACTGGACCTAAGGATTGTCTTCGGTCTATTATGAGAAGAGTGAACCACAAAGATCCTCACGTTGCTATGCAGGCTTTGACTCTTCTAG
G Q S R T G P K D C L R S I M R R V N H K D P H V A M Q A L T L L G

<300

GAGCATGTGTATCAAACTGTGGCAAAATTTTTCATTTAGAAGTATGTTCAAGAGATTTTGCTAGTGAAGTAAGCAACGTATTAAATAAGGGTCATCCTAA
A C V S N C G K I F H L E V C S R D F A S E V S N V L N K G H P K

<400

AGTATGTGAAAAATTAAAGGCTCTTATGGTTGAATGGACAGATGAATTTAAGAATGATCCACAGCTTAGTCTAATATCAGCAATGATTAAGAACCTTAAG
V C E K L K A L M V E W T D E F K N D P Q L S L I S A M I K N L K

<500

GAACAAGGAGTTACGTTCCCAGCTATTGGCTCTCAGGCTGCAGAACAAGCAAAAGCAAGCCCAGCTCTTGTAGCCAAGGATCCTGGTACTGTGGCTAACA
E Q G V T F P A I G S Q A A E Q A K A S P A L V A K D P G T V A N K

<600

AAAGAAGAAGAAGATTTAGCAAAAGCCATTGAGTTGTCTCTCAAGGAACAAAGGCAGCAGTCAACCACCCTTTCCACTTTGTATCCAAGCACATCCAGTC
K E E E D L A K A I E L S L K E Q R Q Q S T T L S T L Y P S T S S L

<700

TCTTAACTAACCACCAACATGAAGGCCGAAAAGTTCGTGCTATATATGACTTTGAAGCTGCTGAAGACAATGAACTTACTTTTAAAGCTGGAGAAATTAT
L T N H Q H E G R K V R A I Y D F E A A E D N E L T F K A G E I I

<800

TACAGTTCTTGATGACAGTGATCCTAACTGGTGGAAAGGTGAAACCCATCAAGGCATAGGGTTATTTCCTTCTAATTTTGTGACTGCAGATCTCACTGCT
T V L D D S D P N W W K G E T H Q G I G L F P S N F V T A D L T A

<900

GAACCAGAAATGATTAAAACAGAGAAGAAGACGGTACAATTTAGTGATGATGTTCAGGTAGAGACAATAGAACCAGAGCCGGAACCAGCCTTTATTGATG
E P E M I K T E K K T V Q F S D D V Q V E T I E P E P E P A F I D E

<1000

AAGATAAAATGGACCAGTTGCTACAGATGCTGCAAAGTACAGACCCCAGTGATGATCAGCCAGACCTACCAGAGCTGCTTCATCTTGAAGCAATGTGTCA
D K M D Q L L Q M L Q S T D P S D D Q P D L P E L L H L E A M C H

<1100

CCAGATGGGACCTCTCATTGATGAAAAGCTGGAAGATATTGATAGAAAACATTCAGAACTCTCAGAACTTAATGTGAAAGTGATGGAGGCCCTTTCCTTA
Q M G P L I D E K L E D I D R K H S E L S E L N V K V M E A L S L

<1200

TATACCAAGTTAATGAACGAAGATCCGATGTATTCCATGTATGCAAAGTTACAGAATCAGCCATATTATATGCAGTCATCTGGTGTTTCTGGTTCTCAGG
Y T K L M N E D P M Y S M Y A K L Q N Q P Y Y M Q S S G V S G S Q V

<1300

TGTATGCAGGGCCTCCTCCAAGTGGTGCCTACCTGGTTGCAGGGAACGCGCAGATGAGCCACCTCCAGAGCTACAGTCTTCCCCCGGAGCAGCTGTCTTC
Y A G P P P S G A Y L V A G N A Q M S H L Q S Y S L P P E Q L S S

<1400

TCTCAGCCAGGCAGTGGTCCCACCATCCGCAAACCCAGCCCTTCCTAGTCAGCAGACTCAGGCCGCTTACCCAAATACAATGGTCAGTTCCGTTCAAGGA
L S Q A V V P P S A N P A L P S Q Q T Q A A Y P N T M V S S V Q G

<1500

AACACATATCCCAGCCAGGCGCCAGTATATAGTCCTCCTCCTGCCGCTACTGCTGCTGCTGCAACTGCCGATGTCACTCTGTACCAGAATGCAGGACCTA
N T Y P S Q A P V Y S P P P A A T A A A A T A D V T L Y Q N A G P N

<1600

ATATGCCCCAGGTGCCAAACTATAACTTAACATCATCAACTCTGCCTCAGCCCGGAGGCAGCCAACAGCCACCTCAGCCACAGCAACCATATTCTCAGAA
M P Q V P N Y N L T S S T L P Q P G G S Q Q P P Q P Q Q P Y S Q K
ßGTATAAGAGTCTT
ApaI
hRluc
Reverse
GGCTCTGCTAGGGCCCGGGATCCCACCGGCTAGAGCCACCATGACTTCGAAAGTTTATGATCCAGAACAAAGGAAACGGATGATAACTGGTCCGCAGTGG
A L L G P G I P P A R A T M T S K V Y D P E Q R K R M I T G P Q W
CCGAGACGATCCCGGGTATA
Primer
TGGGCCAGATGTAAACAAATGAATGTTCTTGATTCATTTATTAATTATTATGATTCAGAAAAACATGCAGAAAATGCTGTTATTTTTTTACATGGTAACG
W A R C K Q M N V L D S F I N Y Y D S E K H A E N A V I F L H G N A

<1700

CGGCCTCTTCTTATTTATGGCGACATGTTGTGCCACATATTGAGCCAGTAGCGCGGTGTATTATACCAGACCTTATTGGTATGGGCAAATCAGGCAAATC
A S S Y L W R H V V P H I E P V A R C I I P D L I G M G K S G K S

<2000

TGGTAATGGTTCTTATAGGTTACTTGATCATTACAAATATCTTACTGCATGGTTTGAACTTCTTAATTTACCAAAGAAGATCATTTTTGTCGGCCATGAT
G N G S Y R L L D H Y K Y L T A W F E L L N L P K K I I F V G H D

<2100

TGGGGTGCTTGTTTGGCATTTCATTATAGCTATGAGCATCAAGATAAGATCAAAGCAATAGTTCACGCTGAAAGTGTAGTAGATGTGATTGAATCATGGG
W G A C L A F H Y S Y E H Q D K I K A I V H A E S V V D V I E S W D

<2200

ATGAATGGCCTGATATTGAAGAAGATATTGCGTTGATCAAATCTGAAGAAGGAGAAAAAATGGTTTTGGAGAATAACTTCTTCGTGGAAACCATGTTGCC
E W P D I E E D I A L I K S E E G E K M V L E N N F F V E T M L P

<2300

ATCAAAAATCATGAGAAAGTTAGAACCAGAAGAATTTGCAGCATATCTTGAACCATTCAAAGAGAAAGGTGAAGTTCGTCGTCCAACATTATCATGGCCT
S K I M R K L E P E E F A A Y L E P F K E K G E V R R P T L S W P

<2400

CGTGAAATCCCGTTAGTAAAAGGTGGTAAACCTGACGTTGTACAAATTGTTAGGAATTATAATGCTTATCTACGTGCAAGTGATGATTTACCAAAAATGT
R E I P L V K G G K P D V V Q I V R N Y N A Y L R A S D D L P K M F

<2500

TTATTGAATCGGACCCAGGATTCTTTTCCAATGCTATTGTTGAAGGTGCCAAGAAGTTTCCTAATACTGAATTTGTCAAAGTAAAAGGTCTTCATTTTTC
I E S D P G F F S N A I V E G A K K F P N T E F V K V K G L H F S

<2600

GCAAGAAGATGCACCTGATGAAATGGGAAAATATATCAAATCGTTCGTTGAGCGAGTTCTCAAAAATGAACAA
Q E D A P D E M G K Y I K S F V E R V L K N E Q

<1800

<1900

<2673

Figure 9. T7-STAM1-Rluc Sequence Map. Representative map of the nucleotide and
amino acid sequence of T7-STAM-1, with Rluc attached at the 3’/C-terminal end, located
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in the pRluc-N1(h) plasmid. Based on sequencing results of ligation product. Included
are the sequences of forward and reverse primers used, located where they are expected
to anneal during PCR.
A map of the entire resulting T7-STAM1-Rluc plasmid was then created, based
on an existing pRluc-N1(h) plasmid map, by adding the T7-STAM-1 sequence to the
location between the HindIII and ApaI restriction sites used to ligate the sequence into
the MCS (Figure 10). 50

Figure 10. T7-STAM1-Rluc Plasmid Map. Plasmid map of the T7-STAM1-Rluc
construct created based on insertion of T7-STAM-1 into the existing pRluc-N1(h)
plasmid map between the HindIII and ApaI restriction sites.
T7-STAM1-Rluc Protein Expression. Following large-scale DNA extraction,
HeLa cells were transfected with T7-STAM1-Rluc to test for expression of the protein.
Whole cell lysates were analyzed by 10% SDS-PAGE, and Western blot with an antibody
against T7. The presence of a band at approximately 100 KDa (the expected molecular
weight of T7-STAM1-Rluc) indicates successful expression of the T7-STAM1-Rluc in
HeLa cells (Figure 11).
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Figure 11. T7-STAM1-Rluc Protein Expression. Western blot image of whole cell
lysates from HeLa cells transfected with T7-STAM1-Rluc DNA and empty pRluc-N1
vector. The presence of a band just above 100 kilodalton (KDa) is indicative of
successful expression of T7-STAM1-Rluc in HeLa cells. Loading was confirmed by
Ponceau stain (data not shown).
T7-STAM1-Rluc and β-Arrestin1-GFP Interact
The goal of subsequent experiments was to determine whether the T7-STAM1Rluc protein interacts directly with the β-arrestin1-GFP protein when co-expressed in
HeLa cells. Co-immunoprecipitation was used to detect this interaction because the
interaction had previously been defined by this method.
β-Arrestin1-GFP Protein Expression. First, it was necessary to examine the
expression of β-arrestin1-GFP in HeLa cells by transfecting increasing concentrations of
DNA and analyzing the expression by subjecting whole cell lysates to 10% SDS-PAGE
and Western blotting with an antibody against GFP (Figure 12). It was noticed that the
expression of this protein produces a “doublet” band, which persisted even at low
concentrations of transfected DNA. It is hypothesized that this doublet corresponds to a
degradation product of the protein that is being formed in the cell.
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Figure 12. β-Arrestin1-GFP Protein Expression. Western blot image of whole cell
lysates from HeLa cells transfected with varying concentrations of β-arrestin1-GFP. The
Western blot was probed with an antibody against GFP and the appearance of doublet
bands at ~75 KDa correspond to the expected molecular weight of β-arrestin1-GFP.
Loading was confirmed by Ponceau stain (data not shown).
T7-STAM1-Rluc/βArrestin1-GFP Interaction Detected by CoImmunoprecipitation. In order to determine whether the Rluc moiety interferes with the
ability of the two proteins to bind, co-immunoprecipitation experiments were performed.
T7-STAM1-Rluc and β-arrestin1-GFP were co-expressed in HeLa cells, and as a control,
each protein was co-transfected with empty vector corresponding to the opposite protein.
T7-STAM-1 was also co-transfected with either β-arrestin1-GFP, or empty pCMV10
vector. Equal amounts of cleared cell lysates from the transfected cells were incubated
with an antibody against T7 and protein A agarose. The precipitated protein was eluted
and analyzed by Western blotting with an antibody against GFP and STAM-1. Figure 13
shows that β-arrestin1-GFP co-purified with both T7-STAM1-Rluc and T7-STAM-1,
suggesting that it interacts with both proteins in HeLa cells.
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Figure 13. Co-Immunoprecipitation of β-Arrestin1-GFP with T7-STAM1-Rluc.
Western blot image of cleared cell lysates and lysate samples subjected to coimmunoprecipitation with an antibody against T7 from transiently transfected HeLa cells.
Immunoprecipitation eluates and cleared cell lysates were subject to 10%SDS-PAGE and
Western blotting with antibodies against GFP and STAM-1 to detect for β-arrestin1-GFP,
T7-STAM1-Rluc, or T7-STAM-1. Image is representative of three independent
experiments.
Figure 13 also shows that only one band is present for β-arrestin1-GFP in the coimmunoprecipitated samples, which corresponds to the top band seen in the “doublet”
produced when probing for β-arrestin1-GFP in cell lysates. This supports the notion that
a degradation product of β-arrestin1-GFP is formed but that only one form of β-arrestin1GFP, presumably the non-degraded form, is capable of co-immunoprecipitating with T7STAM1-Rluc or T7-STAM-1.

Bioluminescence Resonance Energy Transfer (BRET)

43

The manufacturer of the plate reader used for BRET measurements in these
experiments stated that it was not suitable for taking BRET2 readings for reasons
unknown to them. However, they suggested that the plate reader was capable of taking
BRET1 measurements, therefore β-arrestin1-GFP was replaced with β-arrestin1-YFP
(yellow fluorescent protein; plasmid purchased from Addgene) in order to perform
BRET1 experiments with T7-STAM1-Rluc instead.
It is believed that the co-immunoprecipitation of T7-STAM1-Rluc with βarrestin1-GFP is sufficient evidence that the β-arrestin1-YFP protein is capable of
interacting with T7-STAM1-Rluc in cells. This is due to the fact that structural
differences between GFP and YFP are limited to a single Thr203àTyr mutation in the
central region of the protein. Moreover, the YFP moiety is still bound to the C-terminus
of β-arrestin-1. It is therefore assumed that this will likely not cause any difference in the
binding ability of β-arrestin1-YFP to T7-STAM1-Rluc.
CXCR4-Rluc and β-Arrestin1-YFP Interaction Measured in Cells Using
BRET. Prior to conducting BRET experiments between T7-STAM1-Rluc and βarrestin1-YFP, a positive control BRET experiment was carried out between CXCR4Rluc and β-arrestin1-YFP, which has previously been shown to produce a measureable
BRET signal. 51 It was important to verify that the protocol developed here was capable
of measuring a legitimate BRET signal.
A representation of experimental design is depicted in Figure 14(a). HeLa cells
grown on 10cm tissue culture plates were co-transfected with 1.0µg CXCR4-Rluc and
1.0µg β-arrestin1-YFP, or with 1.0µg CXCR4-Rluc alone. After 24 hours, cells were

passaged into two 96-well plates for either fluorescence or luminescence readings. A
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plate with black walls and clear-bottomed wells was used for fluorescence measurements
because the microplate reader utilizes an excitation lamp that is located below the well.
Another plate with white walls and opaque-bottomed wells was used for luminescence
emission measurements, which is measured from above the well. The opaque walls
prevent light scattering, and thus, optimize the amount of luminescence detected.
Cells were plated in triplicate sets of two for luminescence readings, and in a
single triplicate set for fluorescence readings. After allowing the cells to grow in the 96well plates for 24 hours, cells in the white plate were serum-starved by incubation in
90µL of “BRET buffer” (PBS containing 0.1% D-glucose) for 3 hours at 37˚C. Following
incubation, one triplicate set of cell populations from each transfection condition in the
white plate was stimulated with 100nM CXCL12, and the other set with 100nM BSA
vehicle solution. These cells were then further incubated for 15 minutes.
Immediately following incubation, a multi-channel pipette was used to add 10µL
of coelenterazine(h) (CEZ) to cells in the white plate to a final concentration of 5µM, in
order to initiate light emission from Rluc at ~470nm, thus, initiating the BRET reaction.
Immediately following the addition of CEZ, luminescence emission at both 470 and 530
nm was measured in each well every 30 seconds, for approximately 30 minutes.
Meanwhile, the media in the black plate was replaced with 100µL of “BRET
buffer” and the level of fluorescence was measured in each well using the plate reader by
exciting YFP at 470nm, and measuring fluorescence emission at 530nm. This
measurement is indicative of the amount of β-arrestin1-YFP expressed.

At each time point measurement a “Net BRET” value was calculated. This is
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indicative of the level of interaction between the two proteins based on being close
enough in proximity to one another so that light transfers from the Rluc moiety attached
to CXCR4 to the YFP moiety attached to β-arrestin-1. This is calculated, firstly, as the
“BRET Ratio” for each time point, as represented in Equation 1, by dividing the
luminescence emission measured from the acceptor moiety (YFP) at 530nm by the
luminescence emission measured from the donor moiety (Rluc) at 470nm.

Equation 1
This BRET ratio value alone inherently contains a certain level of “background”
signal, which can be determined by measuring the BRET ratio from cells expressing the
Rluc fusion protein alone, as is represented in Equation 2.

Equation 2
Finally, the net BRET value adjusted for background signal can be calculated for
each time point, by subtracting the “Background BRET” from the “BRET Ratio” as is
represented in Equation 3.
Equation 3
The net BRET values obtained from both populations of cells expressing CXCR4Rluc and β-arrestin1-YFP, which were stimulated with either CXCL12 or vehicle, were
averaged for each time point between two experiments and were graphed against time, as
is shown in Figure 14(b). The magnitude of the net BRET obtained from the cells
stimulated with CXCL12 was similar to what has been reported in the literature. One

peculiarity however, is that the net BRET obtained from the cells stimulated with
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vehicle was negative in magnitude. A negative net BRET can occur when the BRET ratio
between the Rluc and YFP fusion proteins is lower than that of background BRET. A
reason this may have occurred is that the conditions of this assay were not fully
optimized and a concentration of CXCR4-Rluc that yields the lowest background BRET
signal had not been identified. However, by calculating the area under each curve, an
increase in the overall magnitude of net BRET was seen in the cells that were stimulated
with CXCL12 when compared to cells stimulated with vehicle (Figure 14(c)). At the very
least, it can be determined from these results that the protocol is likely sufficient to detect
a viable BRET signal.

(a)
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Experimental Procedure:
Transfect Cells
24hr

Passage

24hr

CXCL12/Vehicle
Treatment

Fluorescence
Measurement

15min

Manually Add
Coelenterazine(h)

Immediately Measure 470/530nm
Luminescence Every 30sec for 30min

(b)

(c)

CXCR4-Rluc vs !-Arrestin1-YFP:
Avg NET BRET Values
0.10

Area Under the Curve
0.75

Veh

0.08

CXCL12

0.50

0.06

0.25

AUC

Net BRET

0.04
0.02
0.00
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10

15

-0.02
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25

0.00
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-0.75
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Figure 14. Positive Control BRET Experiment Between CXCR4-Rluc and βArrestin1-YFP. (a) Representation of the sequence of steps used in positive control
BRET experiments. (b) Net BRET values calculated at each time point and averaged
between two independent experiments with error bars representing the standard
deviation. (c) The area under the average net BRET curves from cells stimulated with
CXCL12 or vehicle were calculated separately for each independent experiment and
subsequently averaged together and graphed with error bars representing standard
deviation. N=2.

BRET Protocol Modifications. Much was learned about the nuances of
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performing BRET experiments by performing the positive control experiments. This led
to updates to the protocol that were used for all remaining BRET experiments performed
in this project (summarized in Figure 15). No major aspects of the protocol were omitted,
with the exception of consolidation to a single white, clear-bottomed 96-well plate, in
which fluorescence could also be measured. Following fluorescence measurement, white
tape was placed underneath the plate over the clear-bottomed wells in order to measure
luminescence. In addition, a fluidics module on the plate reader was used for addition of
CEZ to cells. It took, at most, 2.5 min for the plate reader to distribute CEZ to the cells.
Moreover, it was discovered that a “peak luminescence” emission level is reached
approximately 5 minutes after addition of CEZ, and thus luminescence measurements
began being taken after this had occurred, since the BRET signal becomes more stable as
it enters a “slow decay” phase. Finally, a “total luminescence” measurement was added to
the protocol in order to perform measurement of the level of Rluc fusion protein
expression in experiments. This measurement was taken immediately prior to
luminescence measurements at 470nm and 530nm being taken, 5 minutes after addition
of CEZ, at which peak luminescence emission was expected to occur. This measurement
consisted of the luminescence emission magnitude across all wavelengths between 360
and 630nm.
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Figure 15. Modified BRET Protocol. Representation of experimental procedure used to
perform remaining BRET experiments, which is slightly modified from that which was
used to perform positive control experiments shown in Figure 3-9(a).
T7-STAM1-Rluc DNA Concentration Optimized. After performing the
positive control experiments, the next step was to determine whether an interaction
between T7-STAM1-Rluc and β-arrestin1-YFP could be detected. However, before cotransfecting both plasmids, experiments were performed to determine the lowest

concentration of T7-STAM1-Rluc DNA that would yield the lowest background
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BRET signal.
In order to determine the optimal concentration, HeLa cells were transfected with
titrated concentrations of T7-STAM1-Rluc DNA ranging from 0.05 to 0.8µg and BRET
ratios were obtained according to the protocol outlined in Figure 14(a). The net BRET
values obtained over the 30-minute period for each DNA concentration were then
averaged, as shown in Figure 16. The graph indicates that a continual increase in DNA
concentration will cause the background BRET ratio to reach a minimum of
approximately 0.8, and that 0.6µg of T7-STAM1-Rluc DNA is the lowest concentration
that can achieve this minimum. Therefore, it was determined that 0.6µg of T7-STAM1-
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Figure 16. Background BRET Level Optimized. Background BRET signal measured
at increasing concentrations of T7-STAM1-Rluc DNA. Each point represents an average
BRET Ratio obtained for each transfection condition, which were then averaged from
three independent experiments. Error bars represent standard deviation between
experiments. The raw luminescence values measured for each transfection condition were
also averaged for each transfection condition, and averaged between the three
experiments. These values are plotted against the Y-axis on the right with error bars
representing standard deviation between experiments.

T7-STAM1-Rluc and β-Arrestin1-YFP Interaction Likely Measured in
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Cells Using BRET. The next experiment sought to determine whether a BRET signal can
be detected between T7-STAM1-Rluc and β-arrestin1-YFP intracellularly. This was
achieved by a titration of the β-arrestin1-YFP DNA concentration that was co-transfected
with a constant concentration (0.6µg) of T7-STAM1-Rluc DNA and measuring the
corresponding net BRET. Net BRET values for each concentration of β-arrestin1-YFP
were then graphed, and graphs were used to determine whether a BRET interaction is
occurring by analyzing the shape of the resulting curve.
It is logical to assume that if the two proteins are not interacting, net BRET would
increase with increasing DNA concentrations in a linear fashion without saturating, due
only to the increased occurrence of random interactions. Additionally, it is logical to
assume that if the two proteins are interacting, only a relative maximum amount of net
BRET could be measured with increasing DNA concentration, limited by the total
number of expressed fusion proteins in the cell. Therefore, the graph of net BRET with
increasing concentrations of β-arrestin1-YFP should produce a hyperbolic curve that is
saturating at higher concentrations of β-arrestin1-YFP, if the proteins are interacting, and
a linear, non-saturating line if the two proteins are not interacting.
Figure 17(a) shows the net BRET values obtained between T7-STAM1-Rluc and
β-arrestin1-YFP using an x-axis commonly used in the literature to normalize net BRET
to the relative transfection efficiency of the YFP and Rluc fusion proteins. This is
achieved by dividing the total fluorescence by the total luminescence emission measured
for each transfection condition, and using this ratio as the x-value.
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Figure 17. BRET Experiment Between T7-STAM1-Rluc and β-Arrestin1-YFP. (a)
Average of net BRET values from at least four independent experiments for each amount
of β-arrestin1-YFP DNA transfected. Each point is graphed against its corresponding
ratio of YFP fluorescence to total luminescence measurements averaged among
experiments and normalized to 0µg β-arrestin1-YFP. Error bars represent standard
deviation. Curve fit generated using hyperbolic non-linear regression analysis in
Prism/GraphPad 6.0 software. Goodness of fit test produced an R2 value of 0.553,
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indicating that the graph is trending towards saturation. (b) Raw luminescence values
measured at 470 and 530nm for each transfection condition averaged in each experiment,
and further averaged among experiments. Values obtained from each individual
experiment are plotted. Error bars represent standard deviation. (c) YFP fluorescence
measurements from each transfection condition, representing the level of β-arrestin1-YFP
expression, normalized to 0µg β-arrestin1-YFP transfection condition. Bars represent
average among experiments with error bars representing standard deviation. (d) Raw
YFP fluorescence measurements from each experiment for each transfection condition
(not normalized). Error bars represent standard deviation among triplicate measurements.
(e) “Total luminescence” measurements from each transfection condition, representing
expression level of T7-STAM1-Rluc, normalized to 0µg β-arrestin1-YFP transfection
condition. Bars represent average among experiments with error bars representing
standard deviation. (f) Raw total luminescence measurements from each experiment for
each transfection condition (not normalized). Error bars represent standard deviation
among triplicate measurements. RLU: Relative Luminescence Units. RFU: Relative
Fluorescence Units.
Figure 17(a) shows a curve fit that is non-linear in shape and appears to be
approaching saturation at approximately 0.04, which is likely indicative of at least a
slight interaction being detected between T7-STAM1-Rluc and β-arrestin1-YFP.
It is important to note that there is a large amount of variability in net BRET
magnitude measured between experiments, as represented by the relatively large error
bars in Figure 17(a). This can be explained by the wide distribution of average raw
luminescence magnitudes that were measured for each transfection condition in each
experiment (Figure 17(b)), indicating that this variability was intra-experimental. This is
supported by the varied β-arrestin1-YFP and T7-STAM1-Rluc expression levels seen
among corresponding experiments (Figure 17(c) and (e)). However, the expression level
of either fusion protein in each individual experiment (Figure 17(d) and (f)) followed a
similar trend whereby β-arrestin1-YFP expression increased in a way that correlated to
the concentration of DNA used, and T7-STAM1-Rluc expression was relatively equal in
all conditions corresponding to the constant concentration of DNA that was used. It was
assumed that varying cell density and/or viability at the time of BRET measurement was

a large contributing factor to this intra-experimental variability, since the cells were
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subjected to multiple harsh conditions such as being out of the incubator for 20 minutes
and undergoing multiple treatments before readings could be taken.
As a result of this large intra-experimental variability the hyperbolic shape of the
curve is affected, however, the resulting net BRET values obtained by averaging each
experiment still indicate how the net BRET obtained from varying DNA concentrations
relate to one another. It can be concluded, therefore, that it is still possible to analyze net
BRET values for a trend that is indicative of the nature of the interaction between the two
proteins. This trend appears to be approaching saturation, as is supported by the goodness
of fit test R2 value of 0.55.
Another interesting aspect of the results in Figure 17(a) is that they also indicate
that the magnitude of the net BRET obtained is extremely small (<0.1), which is due to
the low efficiency of energy transfer between Rluc and YFP. It is assumed that if the
amount of light transfer from Rluc to YFP were only 50% efficient, meaning that half of
the light emitted by Rluc was detected at 470nm and the other half was absorbed by YFP
and emitted at 530nm, an equal amount of light would be measured at both wavelengths
and yield a net BRET value of 1. However, it has been well documented that the energy
transfer seen with BRET1 (using this variant of Rluc, YFP, and the substrate
coelenterazine (h)) is very low, and despite low energy transfer efficiency, it is still
possible to conclude that an interaction may be being measured between T7-STAM1Rluc and β-arrestin1-YFP in these experiments due to the fact that the net BRET curve
appears to be approaching saturation.

Finally, it can be postulated from Figure 17 that if this BRET assay were to be
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used to study the effects of various factors on the interaction between these two proteins,
4.8µg β-arrestin1-YFP DNA would be an ideal concentration with 0.6µg of T7-STAM1Rluc DNA to obtain the most robust BRET signal.
Non-Specific Interaction Between T7-STAM1-Rluc and EYFP Detected by
BRET. Negative control BRET experiments were conducted so that a graph of net BRET
between two proteins that are not expected to interact could be obtained for comparison
with the shape of the curve obtained from T7-STAM1-Rluc and β-arrestin1-YFP. These
experiments were carried out by co-transfecting increasing concentrations of the empty
YFP plasmid with a constant amount of T7-STAM1-Rluc DNA. The resulting net BRET
values were plotted against corresponding ratios of fluorescence to total luminescence
measured for each transfection condition, as shown in Figure 18(a).
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Figure 18. BRET Experiment Between T7-STAM1-Rluc and pEYFP.
(a) Average of net BRET values from three independent experiments for each
concentration of pEYFP DNA. Each point is graphed against its corresponding ratio of
YFP fluorescence to total luminescence measurements averaged among experiments and
normalized to 0µg pEYFP. Error bars represent standard deviation. Curve fit generated
using hyperbolic non-linear regression analysis in Prism/GraphPad 6.0 software.
Goodness of fit test produced an R2 value of 0.88. (b) Raw luminescence values
measured at 470 and 530nm for each transfection condition averaged in each experiment,
and further averaged among experiments. Values obtained from each individual
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experiment are plotted. Error bars represent standard deviation. (c) YFP fluorescence
measurements from each transfection condition, representing the level of pEYFP
expression, normalized to 0µg pEYFP transfection condition. Bars represent average
among experiments with error bars representing standard deviation. (d) Raw YFP
fluorescence measurements from each experiment for each transfection condition (not
normalized). Error bars represent standard deviation among triplicate measurements. (e)
“Total luminescence” measurements from each transfection condition, representing
expression level of T7-STAM1-Rluc, normalized to 0µg pEYFP transfection condition.
Bars represent average among experiments with error bars representing standard
deviation. (f) Raw total luminescence measurements from each experiment for each
transfection condition (not normalized). Error bars represent standard deviation among
triplicate measurements. RLU: Relative Luminescence Units. RFU: Relative
Fluorescence Units.
Figure 18(a) shows that the net BRET graph obtained from T7-STAM1-Rluc and
EYFP forms a very straight line that does not appear to tend towards any maximum
value. This supports the idea that any interactions occurring between these two proteins
are non-specific, since it is assumed that any BRET under these conditions could only
occur as a result of random intracellular interactions allowing the Rluc moiety to come
within viable distance of the widely distributed YFP protein for BRET to occur.
Therefore, it is expected that these values should result in a line that increases linearly,
with no relative maximum net BRET being achieved.
It is interesting to note that there is less intra-experimental variation in the net
BRET values obtained between T7-STAM1-Rluc and EYFP than those obtained between
T7-STAM1-Rluc and β-arrestin1-YFP, as indicated by the error bars in Figure 18(a).
This is supported by the average raw luminescence values measured from each
experiment (Figure 18(b)), which have more narrowly distributed magnitudes. Further, it
can be seen from Figure 18(c) and (d) that the expression of EYFP correlates well with
the increase in pEYFP DNA concentration, which likely resulted in lower intraexperimental variability. Interestingly, Figure 18(e) and (f) show a trend of T7-STAM1-

Rluc expression that appears to decrease at higher DNA concentrations, although the

58

T7-STAM1-Rluc expression with 0 - 3.6 µg pEYFP are relatively similar, and produce a
linear net BRET relationship.
It was rather surprising, however, that the magnitude of the net BRET values, and
the slope of the line were both higher than expected. When the magnitude of the net
BRET values in Figure 17(a) are compared with those in Figure 18(a), it can be seen that
the magnitude of net BRET between T7-STAM1-Rluc and β-arrestin1-YFP is lower than
those between T7-STAM1-Rluc and pEYFP. This is the opposite of what was expected,
since it is assumed that the occurrence of random interactions between T7-STAM1-Rluc
and pEYFP would be less frequent than the specific interactions between T7-STAM1Rluc and β-arrestin1-YFP. However, it is likely that T7-STAM1-Rluc is highly localized
intracellularly, since it has been previously shown that STAM-1 forms highly organized
puncta in cells with and without CXCL12 stimulation. 37 Therefore, because YFP is
known to distribute widely throughout the cytosol when it is expressed, the chances that
it will randomly encounter T7-STAM1-Rluc are inherently very high. One possible
interpretation of these data is that the intracellular interaction between STAM-1 and βarrestin-1 is simply a weak one.
Moreover, the high level of variability seen in the experiments between T7STAM1-Rluc and β-arrestin1-YFP makes it difficult to compare the magnitude of the net
BRET values between the two experiments. Therefore, the most important comparison
that should be made between the two figures is the shape of each curve. While it is likely
that aspects of this assay could be improved in order to see a stronger signal between
these two proteins, the data presented here still seem to show evidence of a specific

interaction occurring between T7-STAM1-Rluc and β-arrestin1-YFP, which is

59

measurable by BRET.
No Increase in T7-STAM1-Rluc/β-Arrestin1-YFP BRET is Observed Upon
Stimulation with CXCL12. Finally, it has been previously shown by coimmunoprecipitation that the level of interaction between STAM-1 and β-arrestin-1
increases upon stimulation of cells with CXCL12, reaching a maximal interaction at
approximately 30 minutes. 37 Therefore, it was investigated whether there was any
increase in interaction between T7-STAM1-Rluc and β-arrestin1-YFP detected by BRET,
in cell populations that had been stimulated with CXCL12 compared those stimulated
with vehicle.
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Figure 19. T7-STAM1-Rluc/β-Arrestin1-YFP BRET in Cells Stimulated with
CXCL12 vs. Vehicle. The area under the curve formed by the net BRET values from
each time point in two BRET experiments between T7-STAM1-Rluc and β-arrestin1YFP for cells that were stimulated with CXCL12 or vehicle was calculated and averaged
among experiments for the listed transfection conditions cells. Averages graphed with
error bars representing standard deviation between experiments. AUC: Area Under the
Curve.

Calculating the area under the net BRET curve from multiple transfection
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conditions between two experiments (Figure 19) revealed that there is no significant
difference in net BRET magnitude between cells stimulated with CXCL12 and cells
stimulated with vehicle. This is likely due to the fact that the BRET signal is already
maximal as a result of optimization, and that in order to observe a change in net BRET,
the levels of either protein may need to be decreased.

CHAPTER 4
DISCUSSION
Primarily, it is pertinent to state that the results presented here, in their very
essence, are a methods-based development of a novel BRET assay attempting to detect a
direct interaction between STAM-1 and β-arrestin-1 expressed in a mammalian cellular
system. With the nature of these results in mind, it can be seen that this project has, at the
very least, laid the groundwork for a detailed method with which further studies of the
interaction between STAM-1 and β-arrestin-1, as well as the effect of various factors on
this interaction, could likely be performed. The assay could also potentially be applied to
kinetic studies characterizing the binding affinity of these proteins for one another, as
well as to examine functional outcomes of other protein interactions by measuring the
BRET signal following overexpression, or knock-down. Of particular interest, this assay
could potentially be applied to the search for inhibitors of the STAM-1 and β-arrestin-1
interaction. The discovery of an inhibitor would, firstly, allow for further functional cellsignaling assays to be performed with the inhibitor to study functional outcomes on other
signaling molecules. Secondly, an inhibitor of this interaction could be explored as a
possible therapeutic for the prevention of cancer metastasis.
Various caveats, however, were encountered while attempting to establish this
assay that leave some unanswered questions regarding both the sensitivity of the assay
and the nature of the interaction between STAM-1 and β-arrestin-1, which need to be
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considered when moving forward with additional studies. These questions will be
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addressed in the discussion of results and future directions.
Discussion of Results
Successful Expression of T7-STAM1-Rluc. Transfection of mammalian cells
with the engineered T7-STAM1-Rluc construct led to the successful expression of the
STAM-1 protein fused at its C-terminus to an Rluc moiety that is capable of taking part
in a reaction with the coelenterazine(h), and emitting luminescence. This conclusion is
supported by agarose gel purification, sequencing, Western blotting, and luminescence
measurement data. This construct is not only useful in providing opportunities for further
study of the interaction between T7-STAM1-Rluc and β-arrestin1-YFP, but also for other
possible future BRET studies with STAM-1 and other YFP-tagged proteins.
Interaction Between T7-STAM1-Rluc and β-Arrestin1-GFP/YFP Verified by
Co-IP. It is clear from the results of the co-IP experiments that T7-STAM1-Rluc protein
interacts directly with β-arrestin1-GFP protein. However, the amount of β-arrestin1-GFP
that was pulled down with T7-STAM1-Rluc was somewhat small, which could be
indicative of a number of different phenomena occurring within the cell. Firstly, the
interaction between T7-STAM1-Rluc and β-arrestin1-GFP in HeLa cells could simply be
a weak and transient interaction. Secondly, β-arrestin-1 is known to bind to many
different receptors, and sometimes in a somewhat non-specific manner, which may be
causing a significant portion of β-arrestin-1-GFP to be bound to proteins other than T7STAM1-Rluc in different cellular compartments. 59 This may result in difficulty pulling
down a substantial amount of β-arrestin-1-GFP with T7-STAM-1-Rluc.

Another possibility is that degradation of β-arrestin-1-GFP is preventing a
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larger proportion from interacting with T7-STAM1-Rluc. This may be supported by data
obtained in this project where expression of β-arrestin-1-GFP showed a “doublet” band
that may be indicative of formation of a degradation product of β-arrestin-1-GFP. This
was further supported by the fact that only the top band in the doublet appeared to co-IP
with T7-STAM1-Rluc.
The Equipment and Protocol Are Sufficient to Perform BRET Experiments.
A FlexStation3© Multi-Detection Reader (Molecular Devices) was available to perform
BRET experiments. This equipment contains an apparatus capable of detecting < 2
fg/well firefly luciferase in a 96-well plate, luminescence emission wavelengths from 250
to 850 nm, and performing luminescence measurements at more than one wavelength in
each well for each time point. Although this type of plate reader has not been widely used
to perform BRET experiments, it was reasonable to suggest that, considering the listed
specifications, it was capable.
The protocol that was developed to perform BRET experiments in this project
was based on several published protocols that have previously been established.
However, it was necessary to ensure that our application of these protocols was sufficient
to detect a genuine protein interaction by BRET. Therefore, prior to attempting BRET
measurements between T7-STAM1-Rluc and β-arrestin1-YFP, measurements were taken
between proteins known to interact directly.
An interaction between CXCR4-Rluc and β-arrestin1-YFP has previously been
shown in the literature to be measureable by BRET. 51 Thus, this experiment was used as
a positive control in this project to determine that the equipment and the designed

protocol were likely capable of detecting an interaction between two proteins by
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BRET. After obtaining what appeared to be a BRET signal between these two proteins, it
was possible to begin optimizing the experimental conditions for detection of interactions
between T7-STAM1-Rluc and β-arrestin1-YFP.
Determination of the Optimal Concentration of T7-STAM1-Rluc DNA for
Transfection. To develop a BRET assay to measure the interaction between two proteins
that have not previously been studied by BRET, it is necessary to optimize the
concentration of DNA for transfection of each fusion protein in order to achieve the
optimal amount of signal. This requires separate titrations of each protein, and it is best to
begin with the Rluc fusion protein. This is because the expression of this protein alone
defines the background BRET for each experiment and it is ideal to work with the
smallest concentration of DNA that yields the lowest amount of background signal.
Following titration of T7-STAM1-Rluc DNA, it was determined that there was a
relative minimum background BRET signal obtained with increasing DNA concentration.
This can be seen from the sigmoidal relationship that exists between each point on the
graph of net BRET obtained for increasing concentration of DNA, and this is supported
by a very small error that was achieved across experiments. From analysis of this net
BRET curve, it can be said with relatively high certainty that the lowest concentration of
DNA that produced the relative minimum background BRET signal was 0.6 µg.
Potential Measurement of T7-STAM1-Rluc and β-Arrestin1-YFP Interaction
by BRET. The nature of the curve resulting from graphing an average value of the total
fluorescence intensity for each concentration of β-arrestin1-YFP from each experiment
divided by the average value of the total luminescence intensity for each transfection

amount of β-arrestin1-YFP from each experiment was not of a perfect hyperbolic
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shape as would be expected from experiments between two proteins that are directly
interacting. However, the nonlinear regression fit of these points does not appear to
produce a straight line, and appears as though it may be tending toward a maximal net
BRET value in the samples with β-arrestin1-YFP. This especially seems to be supported
by comparison to the net BRET graph of T7-STAM1-Rluc with EYFP, which produces a
very straight line, with no trend toward a maximal signal. In addition, the trend line for
experiments with EYFP was performed separately using a linear and a non-linear
regression curve fit, both of which produced almost identical lines.
The fact that the curve was not of a more obvious hyperbolic shape is likely due
to intra-experimental error, although it may also speak to the possibility that the
interaction between the proteins in the cell is small, which would agree with results
obtained from co-immunoprecipitation experiments suggesting the same conclusion. It
would be very interesting to find an inhibitor of the interaction between these proteins to
see if, despite the fact that the amount of interaction in the cell may be small, the
functional outcome is still large, based on previous results suggesting that the disruption
of the interaction dramatically increases the amount of CXCR4 degradation in the cell.
This could even be potentially advantageous as it might contribute to small effective
doses needed to inhibit the interaction.
It was unexpected that the net BRET values obtained between STAM1-Rluc and
EYFP would reach such high magnitudes at higher concentrations of DNA when
compared to net BRET values obtained between STAM1-Rluc and β-arrestin1-YFP. It
can be postulated that when YFP is presented as a moiety attached to β-arrestin-1, it may

spatially localize with cellular β-arrestin proteins at the plasma membrane, and
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therefore, in a certain number of circumstances, be localized too far from STAM1-Rluc
proteins, localized on endosomes, to yield “bystander BRET.” However, when the EYFP
moiety is expressed alone in the cell, it would likely distribute diffusely throughout the
cytosol, providing more opportunity for “bystander BRET” to occur. Nevertheless, it
appears unlikely that there would be enough “bystander BRET” from random interactions
in the cell to cause higher levels of BRET than from the two proteins directly interacting,
since the distance between the Rluc and YFP moieties needs to be so close (10-100Å) for
BRET to occur. If the β-arrestin-1/STAM-1 interactions in the cell are weak, transient, or
at a low level, as suggested by other results in this project, this could possibly account for
the ability of random interactions between ubiquitously-expressed YFP moieties and
STAM1-Rluc moieties to exceed BRET levels at higher concentrations of DNA.
There were no significant changes in the amount of BRET measured between
cells that had been stimulated with CXCL12 15 minutes prior to BRET measurements
and those that were stimulated with vehicle. The reason for this can only be suggested,
however it seems reasonable to assume that the BRET signal in this system is already
saturated as a result of using optimal concentrations of T7-STAM1-Rluc and β-arrestin1YFP DNA.
Future Directions
There are a few additional assay optimization steps that could be attempted in
order to yield a BRET signal with a larger dynamic range and less error. The most
pertinent would be to create stable cell lines expressing the two fusion proteins, which
would ensure the ubiquitous expression of an equal amount of each fusion protein

throughout cell populations, and eliminate the need for transfection. This would
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improve intra-experiment variability since the magnitude of the total fluorescence, total
luminescence, and BRET signal would not be affected by transfection efficiency, and the
health and homeostasis of the cells would remain intact. A more obvious curved
relationship between BRET measurements would likely be created, whose interruption by
inhibitors would likely be more easily distinguished.
Performing BRET experiments to look for disruption of the interaction between
STAM-1 and β-arrestin-1 using a truncated β-arrestin-1 minigene (“25-161”) would be of
interest, since it has been previously shown by co-immunoprecipitation to disrupt this
interaction. 37 This could help to establish “25-161” as a viable inhibitor of this
interaction for future experiments, and could also serve as a valid positive control for
screening small molecule libraries for inhibitors. However, such experiments would
require optimization of the DNA concentration for co-transfection. Transfection with the
optimal concentrations of T7-STAM1-Rluc and β-arrestin1-YFP DNA (0.6 µg and 4.8µg,
respectively) would leave the highest concentration of “25-161” DNA as 4.6 µg without
exceeding the recommended 10 µg DNA per 10cm dish. The expression of this
concentration is lower than the β-arrestin1-YFP DNA to bind to STAM-1, the expression
of which are competing in the cell. This may mean that greater amounts of “25-161”
DNA would need to be used. In addition, when performing titration experiments of “25161” DNA concentration co-transfected with T7-STAM1-Rluc and β-arrestin1-YFP
DNA, the total DNA concentrations per plate need to be equalized with empty vector
DNA. If the samples of prepared DNA are not at a high enough concentration, there is a
risk that the volume of combined DNA will exceed 20 µL for each transfection condition.

This is another issue that could be minimized by the use of stable cell lines expressing
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the fusion proteins, since it would eliminate the need for co-transfection of T7-STAM1Rluc and β-arrestin1-YFP DNA with “25-161” DNA.
It may also be possible to improve the magnitude of the BRET signal between the
two fusion proteins, although this is not guaranteed. One way to attempt this would be to
change the position of the Rluc and YFP moieties on the STAM-1 and β-arrestin-1
proteins, for instance, swapping the moieties between proteins. It is possible that the
folding of either protein may be affected by the current attached moiety and that more
efficient folding, interaction between the two proteins, or distance between the moieties
could be achieved. Changing the location of the YFP moiety from the C-terminus to the
N-terminus of β-arrestin-1 is not plausible since it is known that the interaction between
β-arrestin-1 and CXCR4 occurs through the positively charged region at the N-terminal
end, and the YFP would likely interfere with the normal functioning of β-arrestin-1.
Moreover, moving the Rluc moiety from the C-terminal to the N-terminal end of STAM1 may not be a good choice since a VHS region is located here, which is known to
interact with regulatory molecules involved in protein sorting to the MVB pathway. Thus,
it is possible that this may stop STAM-1 from functioning correctly. Further, either
moiety could be moved to locations within the middle of the amino acid sequence of
either protein. In order to do this, however, special attention needs to be paid to important
regions involved in the correct folding or functioning of either protein.
Unfortunately, a Z-score could not be calculated for this assay in order to speak to
the fitness of the assay for application to HTS. This was due to the fact that DNA
expressing proteins to produce a maximal net BRET signal was not on hand to perform

positive control experiments that would be needed to calculate a Z-score. However, it
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was still concluded that the dynamic range of the interaction seen here is likely not large
enough for this assay to be used as a HTS for small-molecule inhibitors. One reason for
assuming this was discussed previously regarding the fact that the efficiency of energy
transfer between Rluc and YFP is low, and is likely the largest contributing factor to the
low BRET signal intensity measured in these experiments. A solution to this problem,
which should be considered above all other optimization strategies if BRET is to be used,
is to consider using newer BRET technologies that have been developed in recent years
to improve the energy transfer efficiency. Examples of these newer technologies that
show promise for improved dynamic range include the use of Renilla GFP, nanoBRET,
and different coelenterazine derivatives. The same principles outlined in this project
could be used to establish a BRET signal between STAM-1 and β-arrestin-1 with a larger
dynamic range using any of these newer technologies.
Conclusion
Taking into account all of these data, it can be said that a possibly weak and/or
transient interaction occurs between T7-STAM1-Rluc and β-arrestin1-YFP
intracellularly, which is likely being detected by the BRET method outlined here. There
is some question as to whether the assay is sufficiently optimized for application to
different interaction studies, for instance, screening for small molecule inhibitors. At the
very least, there are certain aspects of this protocol that need to be optimized further, such
as possible assay adjustments to yield a larger dynamic range. The project serves as a
good platform, however, to begin establishing this type of assay.

The data presented also contributes knowledge towards the understanding of
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the nature of the interaction between STAM-1 and β-arrestin-1, and the application of a
version of this assay that is further optimized to study their interaction could shed
additional light on the manner by which these proteins interact. It is important that future
experiments be pursued due to the implications in the understanding, and potential
therapies of certain disease states, especially cancer metastasis.

APPENDIX A
REAGENTS AND BUFFERS WITH RECIPES
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Name of Reagent:
6X Loading Dye
Agarose
Ethidium Bromide
10 Kb Ladder
Bovine Serum Albumin (BSA)
Glycerol
Kanamycin A Monosulfate
Ampicillin
LB Broth Powder
LB BactoTM Agar Powder
Fetal Bovine Serum (FBS)
Polyethylenimine (PEI)
Tris Base
Nonidet P-40 (NP-40)
Aprotinin
Leupeptin
Pepstatin A
Sodium Dodecyl Sulfate (SDS)
β-mercaptoethanol
Bromophenol Blue
Protein-A Agarose
Acrylamide/Bis-acrylamide, 30% solution
2-propanol
TEMED
Ammonium Persulfate (APS)
TWEEN-20
Non-Fat Powdered Milk
Horseradish Peroxidase-Conjugated (HRP)
Antibodies
DURA Extended Duration Substrate
D-Glucose
CXCL12
DPBS
0.05% Trypsin-EDTA
DMEM
Opti-MEM
Coelenterazine(h)
Glacial Acetic Acid
EDTA
100% Ethanol
DMSO
Concentrated HCl
Glycine

Source:
Promega
Dot Scientific, Inc.
Sigma
Invitrogen
Roche
Sigma-Aldrich
Sigma
Sigma
Fisher
Becton, Dickinson and Company (BD)
Sigma
Polysciences, Inc.
Dot Scientific, Inc.
Roche
Roche
Roche
Roche
Dot Scientific, Inc.
Sigma
Sigma
Roche
Sigma
Sigma
Bio-Rad
Sigma
Dot Scientific, Inc.
Roundy’s
Vector
Fisher
Sigma
Protein Foundry
Sigma
Gibco
Sigma
Gibco
Nanolight Technologies
Sigma
Sigma
Sigma
Sigma
Fisher
Dot Scientific
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Methanol
VWR
NaCl
Dot Scientific
CaCl2
Sigma
Ponceau-S
Sigma
Precision Plus ProteinTM All Blue Standards
Bio-Rad
Molecular Weight Marker
Table 11. Reagents Used in This Project. Reagents listed with corresponding vendor
from whom they were purchased.
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TAE Buffer (50X)
2M Tris Base
1M Glacial Acetic Acid
0.05M EDTA, pH 8.0
dH2O
Appropriate amount of tris base weighed and combined with appropriate volumes of
glacial acetic acid and EDTA in partial volume of dH2O. dH2O added to adjust solution
to final volume. Store at room temperature. To make 1X TAE buffer 80mL of 50X TAE
is diluted in 3.92L of dH2O.
LB Broth
5g LB broth powder (Lennox; Thermo-Fischer) weighed and dissolved in 250mL dH2O
in a glass bottle or 1L flask using a stir plate. Bottle/flask autoclaved at 250˚F for 40min
using “Liquid” setting. Stored at room temperature.
LB Agar Plates (with antibiotic)
40g LB BactoTM Agar (Becton, Dickinson and Company) weighed and dissolved in 1L
ddH2O in a 2L flask using a stir plate. Flask autoclaved at 250˚F for 40 min using
“Liquid” setting. After cooling enough to handle flask comfortably with bare hands, but
still warm enough that coagulation has not occurred, 25mg/mL kanamycin A (Sigma) in
ddH2O added to solution to a final concentration of 100µg/mL. Solution poured into

plates under a flame and allowed to cool to room temperature. Plates stored upside
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down at 4˚C for up to 3 months.
Polyethylenimine (PEI; 1mg/mL in 30% Ethanol) Stock Solution
10mg of PEI powder (Polysciences, Inc.) is weighed and poured into a 50mL conical
tube. 3mL of 100% ethanol is added and tube is vortexed and warmed in a 37˚C water
bath until powder has dissolved. Solution is diluted with 7mL of DNAase/RNAse free
H2O to final volume so that final volume is 30% ethanol. Solution filtered through a 2µm
syringe and distributed into 100µL aliquots and stored at -80˚C. Each aliquot is single use
only.
Co-Immunoprecipitation Buffer
50mM Tris-HCl, pH 7.5
150mM NaCl
0.5% NP-40
10µg/mL each: Aprotinin, Pepstatin A, Leupeptin
dH2O to final volume
All ingredients combined in a 50mL conical tube on ice. Solution maintained on ice
while in use and kept at 4˚C when not using.
Protease Inhibitor Cocktail (Aprotinin, Leupeptin and Pepstatin A)
10mg/mL solutions of each protease inhibitor made separately. 50mg Aprotinin (Roche)
and 50mg Leupeptin (Roche) weighed and placed into a 15mL conical tube. 5mL of
dH2O added to tube on ice and tube vortexed to dissolve powder. 10mg of Pepstatin A
weighed and added to a tube, to which 1mL of DMSO is added. 50µL of each solution is
combined in a sterile 650µL Eppendorf tube and stored at -20˚C.

1M Tris-HCl pH7.5, 0.75M Tris-HCl pH 8.8 or 6.5
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Appropriate amount of Tris Base weighed and dissolved in a partial volume of dH2O
using a stir plate. pH meter (GeneMate) used to adjust the pH of the solution to 7.5 by
adding concentrated HCl drop-wise. dH2O is added to solution to final volume. Solution
is sterile-filtered and stored at room temperature.
10% SDS Solution
50g SDS weighed in hood and dissolved in partial volume of dH2O using stir plate. dH2O
added to final volume. Solution sterile-filtered and stored at room temperature.
10% APS Solution
1g ammonium persulfate (APS) weighed and added to a 15mL conical tube. 10mL dH2O
added and powder dissolved by vortexing. Tube wrapped with foil and stored at 4˚C for
up to one month.
10X SDS Running Buffer
0.25M Tris Base
1.92M Glycine
0.14M SDS
dH2O
Appropriate amount of tris base, glycine and SDS weighed and dissolved in partial
volume of dH2O using a stir plate. dH2O added to adjust to final volume. Dilute 400mL
of 10X SDS Running Buffer in 3.6L of dH2O to make 1X SDS Running Buffer.
Transfer Buffer (10X)
0.25M Tris Base
1.92M Glycine

dH2O
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Appropriate amount of tris base and glycine weighed and dissolved in partial volume of
dH2O using a stir plate. dH2O added to adjust to final volume. Store at room temperature.
Transfer Buffer (1X)
Combine 400mL 10X Transfer Buffer with 800mL methanol and 2.8L dH2O. Store at
4˚C.
TBS-T (20X)
3M NaCl
0.4M Tris Base
1% Tween-20
Appropriate amount of tris base and NaCl weighed and dissolved in partial volume of
dH2O using a stir plate. pH meter (GeneMate) used to adjust the pH of the solution to 7.5
by adding concentrated HCl drop-wise. dH2O added to adjust to final volume. To make
1X TBST 200mL of 20X TBST is diluted in 3.8L of dH2O.
2X Sample Buffer
8% SDS
10% Glycerol
0.7M β-Mercaptoethanol
37.5mM Tris-HCl, pH 6.5
0.0003% Bromophenol Blue
Appropriate amount of SDS weighed and combined with appropriate volumes of glycerol
and Tris-HCl, pH 6.5. In a biological safety cabinet appropriate volume of βmercaptoethanol added. Appropriate volume of bromophenol blue added and solution is

mixed using a stir plate until all solids have dissolved. 5mL aliquots are made and
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stored at -20˚C.
BRET Buffer
Dulbecco’s Phosphate Buffered Solution (DPBS)
0.1% D-Glucose
Appropriate volume of D-glucose weighed and poured into DPBS bottle. Bottle is
inverted several times to dissolve D-glucose.
CXCL12 Stock Solution (1000X)
10µM CXCL12
1% BSA in DPBS Solution
CXCL12 powder dissolved in appropriate volume of 1% BSA in DPBS solution and
aliquoted into 650µL microcentrifuge tubes in a biological safety cabinet to maintain
sterility. Tubes stored at -20˚C.
1mM Coelenterazine(h) Stock Solution
Coelenterazine(h) lyophilized powder received in vials that are stored at -80˚C for up to
one year. Appropriate volume of 100% ethanol is added to directly to vial and vortexed to
dissolve powder to make stock solution. Solution is stored at -20˚C for up to 1 month.
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